ÔÇ∑ÔÇ∑
ÔÇ∑Other information as needed to protect confidentiality of [COMPANY_005] or partners, personal
information, or to otherwise protect the integrity
 of the clinical study.Title: A Phase II, Randomized, Double-blind, Safety and Immunogenicity Trial of Norovirus GI.1/
GII.4 Bivalent Virus-Like Particle Vaccine in Healthy Elderly Adults 
Study ID: [REMOVED]
SAP Approve Date:  02 February 2017 
Certain information  within this Statistical Analysis Plan has been  r edacted (ie, specific content is masked 
irreversibly from view with a black/blue bar) to protect either personally identifiable ([COMPANY_003]) information or 
company confidential information (CCI). 
This may include, but is not limited to, redaction of the following: 
Named persons or organizations associated with the study.
Proprietary information, such as scales or coding systems, which are considered confidential  
information under prior agreements with license holder.
 7,7/(3$*(
67$7,67,&$/$1$/<6,63/$1
678'<180%(5125
$3KDVH,,5DQGRPL]HG'RXEOHEOLQG6DIHW\DQG,PPXQRJHQLFLW\ 7ULDORI1RURYLUXV
*,*,,%LYDOHQW9LUXV/LNH3DUWLFOH9/39DFFLQH,Q+HDOWK \(OGHUO\$GXOWV
1256DIHW\DQG,PPXQRJHQ LFLW\RI1RURYLUXV*,*,,%LYDO HQW9/39DFFLQHLQDQ
(OGHUO\3RSXODWLRQ 
3+$6(,,
9HUVLRQ)LQDO
'DWH)HEUXDU\
3UHSDUHGE\ 
%DVHGRQ
3URWRFRO9HUVLRQ3URWRFRO'DWH1RYHPEHU
[COMPANY_003]
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of UseLFLW\7ULFLW\7
+HDOWK\+HDOWK
,*,,*,,
WLRQRQ
(,,,,
HUVLRQUVLRQ)
'DWHDWH
3URWRFRRWRF
3URW3URnon-co
[COMPANY_003]
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
For non-commercial use only and subject to
NOR -204 Page 3 of 41 
Statistical Analysis Plan ( Final 1 .0) [ADDRESS_275245] O F ABBREVIATIONS  ................................ ................................ .............................. 5 
4.0 OBJECTIVES  ................................ ................................ ................................ ...................... 7 
4.1 Primary Objectives ................................ ................................ ................................ ......... 7 
4.2 Secondary Objectives ................................ ................................ ................................ .....7 
4.3 Exploratory Objectives  ................................ ................................ ................................ ..7 
4.4 Study Design  ................................ ................................ ................................ .................. 7 
5.0 ANALYSIS ENDPOINTS  ................................ ................................ ................................ 14 
5.1 Primary Endpoints  ................................ ................................ ................................ .......14 
5.2 Secondary Endpoints  ................................ ................................ ................................ ...14 
5.3 Exploratory Endpoints  ................................ ................................ ................................ .15 
6.0 DETERMINATION OF SAM PLE SIZE  ................................ ................................ .......... 18 
7.0 METHODS OF ANALYSIS AND PRESENTATION  ................................ ..................... 19 
7.1 General Principles  ................................ ................................ ................................ ........ 19 
7.1.1  Study Day and Analysis Window Definitions  ................................ ....................... 20 
7.1.2  Conventions for Handling Missing Values  ................................ ............................ 21 
7.2 Analysis Sets  ................................ ................................ ................................ ................ 22 
7.3 Disposition of Subjects  ................................ ................................ ................................ 24 
7.3.1  Disposition  ................................ ................................ ................................ ............. 24 
7.3.2  Protocol Violations  ................................ ................................ ................................ 24 
7.4 Demographic and Other Baseline Characteristics  ................................ ....................... 25 
7.5 Medical History and Concurrent Medical Conditions  ................................ ................. 25 
7.6 Medication History and Concomitant Medications  ................................ ..................... 25 
7.7 Study Drug Exposure and Compliance  ................................ ................................ ........ 25 
7.8 Immunogenicity Analysis  ................................ ................................ ............................ 26 
7.8.1  Primary Efficacy Endpoint(s)  ................................ ................................ ................ 26 
7.8.2  Secondary Efficacy Endpoint(s)  ................................ ................................ ............ 27 
7.8.3  Additional Immunogenicity Endpoint(s)  ................................ ............................... 30 
7.9 Pharmacokinetic/Pharmacodynamic Analysis  ................................ ............................. 32 
7.9.1  Pharmacokinetic Analysis  ................................ ................................ ...................... 32 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
125 3DJHRI
6WDWLVWLFDO$QDO\VLV 3ODQ)LQDO )HEUXDU\

  3KDUPDFRG\QDPLF$QDO\VLV   
  2WKHU2XWFRPHV   
  6DIHW\$QDO\VLV   
  $GYHUVH(YHQWV   
  &OLQLFDO/DERUDWRU\(YDOXDWLRQV   
  9LWDO6LJQV   
  /HDG(&*V   
  2WKHU2EVHUYDWLRQV5HODWHGWR6DIHW\   
  ,QWHULP$QDO\VLV   
  &KDQJHVLQWKH6WDWLVWLFDO$QDO\VLV3ODQ   
 5()(5(1&(6   


/,672),17(;77$%/(6
7DEOH6XEMHFW'LVWULEX WLRQ)RU7ULDO1RU    
7DEOH6FKHGXOH2I7ULDO3URFHGXUHV    
7DEOH9LVLW :LQGRZV)RU,PPXQRJHQLFLW\ $YLGLW\$QG6DIHW\$QDO\VHV  
7DEOH'HILQLWLRQV2I,P SODXVLEOH0HDVXUHPHQWV    
7DEOH)HYHU&DWHJRUL]DWLRQ    

/,672),17(;7),*85(6
),*85(6&+(0$7,&2)75,$/125'(6,*1   

/,672)$33(1',&(6
$SSHQGL[$  $GYHUVH(YHQWV2I6SHFLDO,QWHUHVW$HVL   
$SSHQGL[%  'DWD0RQLWRULQJ&RPPLWWHH'PF2XWSXWV   
CCI
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use










\
DVXUHPHXUHP

(66
&2&2)7)
1',&(1',&(
$
[%%onlyCCI
125 3DJHRI
6WDWLVWLFDO$QDO\VLV 3ODQ)LQDO )HEUXDU\

/,672)$%%5(9,$7,216
$( $GYHUVH(YHQW
$(6, $GYHUVH(YHQWRI6SHFLDO,QWHUHVW
$O2+ $OXPLQXP+\GUR[LGH$OK\GURJHO¬ä
$1&29$ $QDO\VLVRI&RYDULDQFH
DQWL1R9 DQWLQRURYLUXV
%0, %RG\0DVV,QGH[
%7 %ORFNLQJ7LWHUV
&, &RQILGHQFH,QWHUYDO
 
&52 &RQWUDFW5HVHDUFK2UJDQL]DWLRQ
&65 &OLQLFDO6WXG\5HSRUW
'0& 'DWD0RQLWRULQJ&RPPLWWHH
H&5) HOHFWURQLF&DVH5HSRUW)RUP
('& (OHFWURQLF'DWD&DSWXUH
(/,6$ (Q]\PHOLQNHG,PPXQRVRUEHQW$VVD\
(7 (DUO\7HUPLQDWLRQ
)$6 )XOO$QDO\VLV6HW
*0%7  *HRPHWULF0HDQ%ORFNLQJ7LWHU
*0)5 *HRPHWULF0HDQ)ROG5LVH
*07 *HRPHWULF0HDQ7LWHU
*, *HQRJURXS,
*,, *HQRJURXS,,
*, *HQRJURXS,*HQRW\SH
*,, *HQRJURXS,,*HQRW\SH
*6' *HRPHWULF6WDQGDUG'HYLDWLRQ
+%*$ +LVWREORRG*URXS$QWLJHQ
+,9 +XPDQ,PPXQRGHILFLHQF\9LUXV
,&) ,QIRUPHG&RQVHQW)RUP
,&+ ,QWHUQDWLRQDO&RQIHUHQFHRQ+DUPRQL]DWLRQ
,(& ,QGHSHQGHQW(WKLFV&RPPLWWHH
,)1»ñ ,QWHUIHURQ*D[COMPANY_003]
,J ,PPXQRJOREXOLQ
,/ ,QWHUOHXNLQ
,/ ,QWHUOHXNLQ
,0 ,QWUDPXVFXODU
,:56 ,QWHUDFWLYH:HE5HVSRQVH6\VWHP
//R4 /RZHU/LPLWRI4XDQWLILFDWLRQ
/60V /HDVW6TXDUH0HDQV
0&$5 0LVVLQJ&RPSOHWHO\$W5DQGRP
0HG'5$ 0HGLFDO'LFWLRQDU\IRU5HJXODWRU\$FWLYLWLHVCCI
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of UseD\\
J7LWHU7LWHU
5LVH5LVH
7LWHUHU
,,,,
RXS,*HXS,*
QRJURXS,,JURXS
*HRPHWULHRPHW
+LVWRE+LVW
+X+
//
,0,0
,:
NOR -204 Page 6 of 41 
Statistical Analysis Plan ( Final 1 .0) [ADDRESS_275246] Deviation  
SOC  System Organ Class  
TNF -Œ± Tumor Necrosis Factor -alpha  
ULoQ  Upper Limit of Quantification  
VLP  Virus -like Particles  
WHODrug  World Health Organization Drug Dictionary  
 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
125 3DJHRI
6WDWLVWLFDO$QDO\VLV 3ODQ)LQDO )HEUXDU\

2%-(&7,9(6
7KHSULPDU\VHFRQGDU\DQG H[SORUDWRU\REMHFWLYHVRIWKLVWULD ODUHOLVWHGLQWKHIROORZLQJ
VHFWLRQV
3ULPDU\2EMHFWLYHV
7RVHOHFWIRUIXUWKHUGHY HORSPHQWDIRUPXODWLRQDQGWKHGRVHUH JLPHQRIWKH1R9*,*,,
%LYDOHQW9/39DFFLQHWKDWLVLPPXQRJHQLFDQGVDIHLQDQHOGHUO\ SRSXODWLRQDJHG\HDUVDQG
DERYH
6HFRQGDU\2EMHFWLYHV
x7RDVVHVVWKHLPPXQRJHQLFLW\RIWKH1R9*,*,,%LYDOHQW9/3 9DFFLQHLQERWKDGXOWV
DJHG¬±\HDUVDQGHOGHUO\SRSXO DWLRQDJHG¬ï\HDUVE\WUHD WPHQWDUP
x7RDVVHVVWKHVDIHW\SURILOHRIWKH1R9 *,*,,%LYDOHQW9/3 9DFFLQHLQERWKDGXOWVDJHG
¬±\HDUVDQGHOGHUO\SRSXODWLRQDJHG¬ï\HDUVE\WUHDWPHQW DUPWKURXJKRXWWKHWULDO
([SORUDWRU\2EMHFWLYHV
6WXG\'HVLJQ
7KLVLVD3KDVH,,UDQGR PL]HGFRQWUROOHGGRXEOHEOLQGPXOWL VLWHWULDORIWKH1R9*,*,,
%LYDOHQW9/39DFFLQHDGMXYDQWHGZLWK»ùJ$O2+ ZLWKRXW03/)RUPXODWLRQ$DQGZLWK
»ùJRI03/)RUPXODWLRQ%$SSUR[LPDWHO\VXEMHFWVZLOOE HDOORFDWHGWRDJHJURXSV
¬±¬±¬±DQG¬ï\HDUVRIDJH6XEMHFWVLQWKHHO GHUO\DJHJURXSV¬±¬±
DQG¬ï\HDUVRIDJHZLO OEHUDQGRPL]HGWRDUDWLRIRU WKHGRVHUHJLPHQDQGIRUWKH
IRUPXODWLRQHDFKVXEMHFWZLO OUHFHLYHRUGRVHVRIWKH1R9 *,*,,%LYDOHQW9/39DFFLQH
HLWKHU)RUPXODWLRQ$RU)RUPXODWLRQ% 7KHUHZLOOEHDQLQWHUYD ORIGD\VEHWZHHQWKHWZRCCI
Property of Taked6WXG6WXd subject to the applicable Terms of Use*,,*,,
\HDUV\HDUV
9DFFLQH9DFFL
WPHQWDUPPHQWD
9/39DF/39D
HDWPHQWDDWPHQW
7KLVLV7KLVL
%LYD%LY
eda: For non-commercial use only and 
NOR -204 Page 8 of 41 
Statistical Analysis Plan ( Final 1 .0) 02 February 2017  
 
vaccine  administrations. The 18 ‚Äì49 year old subjects will receive only one NoV G.1/GII.4 
Bivalent VLP Vaccine dose (Formulation A).  
All age groups will be enrolled in parallel. In order to maintain blinding and to have the same 
trial time point with both dosing r egimens relative to the last vaccination, subjects randomized 
into the 1 -dose groups will receive 1 dose of Saline Placebo on Day 1 followed by 1 dose of the 
investigational NoV G.1/GII.[ADDRESS_275247] dose of NoV G.1/GII.4 Bivalent VLP Vaccine on Day 1.  
Planned number of Arms.  
‚Ä¢ Arm 1:  NoV GI.1/GII.4 Bivalent VLP Vaccine, Formulation A, 1 -dose regimen (subjec ts 
‚â•60 years).  
‚Ä¢ Arm 2:  NoV GI.1/GII.4 Bivalent VLP Vaccine, Formulation A, 2 -dose regimen (subjects 
‚â•60 years).  
‚Ä¢ Arm 3:  NoV GI.1/GII.4 Bivalent VLP Vaccine, Formulation B, 1 -dose regimen (subjects 
‚â•60 years).  
‚Ä¢ Arm 4:  NoV GI.1/GII.4 Bivalent VLP Vaccine, Formu lation B, 2 -dose regimen (subjects 
‚â•60 years).  
‚Ä¢ Arm 5:  NoV GI.1/GII.4 Bivalent VLP Vaccine, Formulation A, 1 -dose regimen (Subjects 
18‚Äì49 years).  
All subjects will receive trial vaccination on Day 1 and Day 29 as shown in Table 1 . If Dose 2 is 
not given on Day 29, subsequent visits should be calculated from the actual Day given (e.g., if 
Dose 2 is given on trial Day 31, the next visit should be scheduled for trial Day 38).  
Table [ADDRESS_275248] Distribution fo r Trial NOR -204 
Age groups (years)  Number of subjects  Dose regimen (a) Day 1  Day 29  
18‚Äì49 25 1 Saline Placebo  Formulation A  
60‚Äì74 25 1 Saline Placebo  Formulation A  
25 2 Formulation A  Formulation A  
25 1 Saline Placebo  Formulation B  
25 2 Formulation B Formulation B  
75‚Äì84  25 1 Saline Placebo  Formulation A  
25 2 Formulation A  Formulation A  
25 1 Saline Placebo  Formulation B  
25 2 Formulation B  Formulation B  
‚â•85 25 1 Saline Placebo  Formulation A  
25 2 Formulation A  Formulation A  
25 1 Saline Placebo  Formulation B  
25 2 Formulation B  Formulation B  
Total evaluable subjects  325    
aOne dose versus 2 -dose regimen with the NoV G.1/GII.4 Bivalent VLP Vaccine (Formulations A or B)  
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
125 3DJHRI
6WDWLVWLFDO$QDO\VLV 3ODQ)LQDO )HEUXDU\

7ULDO$UPVDQGZLOOLQFOXGHVXEM HFWVDJHG¬ï\HDUVG LVWULEXWHGLQWRWKUHHDJHJURXSV
LQFOXGLQJ\HDUVDQG¬ï\HDUV7ULDO$UPZLOOL QFOXGHVXEMHFWVDJHG¬±\HDUV
6FUHHQLQJSUH YDFFLQDWLRQEORRGGUDZSUH YDFFLQDWLRQVDOLYDFROOHFW LRQXULQHSUHJQDQF\WHVWLI
DSSOLFDEOHUDQGRPL]DWLRQ DQGYDFFLQDWLRQZLOORFFXURQ'D\ 6FUHHQLQJZLOOLQFOXGH
GHPRJUDSKLFFKDUDFWHULVWLFVPHGLFDOKLVWRU\PHGLFDWLRQKLVWRU \FRQFRPLWDQWPHGLFDWLRQV
SK\VLFDOH[DPLQDWLRQKHLJKWZHLJKWERG\PDVVLQGH[%0,DQG YLWDOVLJQVDQGHOLJLELOLW\
FULWHULDDV VHVVPHQW:ULWWHQLQIRUPHGFRQV HQWZLOOEHREWDLQHGSULRUWRDQ \WULDOVSHFLILF
SURFHGXUHRQ'D\6L[DGGLWLRQDOFOLQLFDOYLVLWVDUHSODQQHG RQ'D\'D\'D\'D\
'D\DQG'D\IRUD OOWKHVXEMHFWV'XULQJWKHVHYLVLWV SRVWLPPXQL]DWLR QVHURORJLF
VSHFLPHQVZLOOEHFROOHFWHGD QGVXEMHFWVZLOOEHIROORZHGIRUV DIHW\DVVHVVPHQWXSWR\HDUDIWHU
WKHODVWWULDOYDFFLQHGRVHLHWKURX JKDQGLQFOXGLQJDODVW YLVLWVFKHGXOHGRQ'D\'LDU\
FDUGVZLOOEHFRPSOHWHGIURP'D\VWKURXJK 6ROLFLWHG$(VZLOOEH DVVHVVHGIRUGD\VWKH
GD\RIYDFFLQDWLRQDQGWKHIROORZLQJGD\VDIWHUHDFKYDFFLQD WLRQDQGXQVROLFLWHG$(VZLOOEH
DVVHVVHGIRUGD\VIROORZLQJHDF KYDFFLQDWLRQ6HULRXV$GYHUV H(YHQWV6$(VDQG$GYHUVH
(YHQWVRI6SHFLDO,Q WHUHVW$(6,ZLOOEHDVVHVVH GWKURXJKRXWWKHWULDO7KHILQDO WULDOYLVLWLV
VFKHGXOHGRQ'D\ 
$UHYLHZRIVDIHW\GDWDZLOO EHSHUIRUPHGE\WKH'DWD0RQLWRULQ J&RPPLWWHH'0&DVVRRQDV
WKHILUVWDSSUR[LPDWHO\VXEM HFWVKDYHFRPSOHWHGWKH'D\ 9LVLWGD\VDIWHUODVW
YDFFLQDWLRQ5HIHUWR6HFWLRQ 
$QLQWHULPDQDO\VLVRQVDIHW\ DQGLPPXQRJHQLFLW\GDWDLVSODQQH GZKHQDOOVXEMHFWVKDYH
FRPSOHWHGWKH'D\9LVLWGD \VDIWHUODVWYDFFLQDWLRQ5H IHUWR6HFWLRQ 7KHILQDO
&OLQLFDO6WXG\5HSRUW&65ZLOOLQFOXGH DQDO\VHVRIDOOVDIHW\DQGLPPXQRJHQLFLW\GDWDWKURXJK
'D\DVZHOODVLQGLYLGXDOVXEM HFWGDWDLQFOXGLQJGDWDOLVW LQJVDQGVXEMHFWWUHDWPHQW
DVVLJQPHQWVCCI
Property of TakedHYLHZRIYLHZR
KHILUVWDKHILUVW
YDFFLQYDFubject to the applicable Terms of UseI

LOLW\LW\
LILFILF
'D\''D\
QVHURORQVHUR
HQWXSWRQWXS
GRQ'D\RQ'D\
HDVVHVVHDVVHVV
DQGXQVRDQGXQ
H(YHQWV(YHQ
WKHWULDOKHWULD
$Qeda: For non-commercial use only and sub
NOR -204 Page 10 of 41 
Statistical Analysis Plan ( Final 1 .0) 02 February 2017  
 
A schematic of the trial design is included as Figure 1 . 
Figure 1 Schematic of Trial NOR -204 Design  
 
Trial Vaccines:  
Norovirus GI.1/GII.4 Bivalent VLP Vaccine:  two vaccine formulations will be evaluated in this 
trial:  
‚Ä¢ Formulation A (per dose): 15 Œºg of GI.1 NoV VLP; 50 Œºg of GII.4 NoV VLP (consensus of 
3 strains) without MPL, all of which are adsorbed to Al(OH) 3 adjuvant (500 ¬µg aluminum).  
‚Ä¢ Formulation B (per dose): 15 Œºg of GI.1 NoV VLP; 50 Œºg of GII.4 NoV VLP (consensus of 
3 strains) with [ADDRESS_275249], all of which are adsorbed to Al(OH) 3 adjuvant (500 ¬µg 
aluminum).  
Control : Placebo (salin e) will be 0.9% sodium chloride for injection without preservative. It will 
be used as a control to maintain the trial blinding in subjects who are in the one -dose groups of 
NoV GI.1/GII.4 Bivalent VLP Vaccine.  
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
NOR -204 Page 11 of 41 
Statistical Analysis Plan ( Final 1 .0) 02 February 2017  
 
All vaccines will be administered by [CONTACT_228666] (IM) route into the middle third of the deltoid 
muscle, preferably in the non -dominant arm.  
Visit Schedule  
Clinical trial visits will be performed on Days 1, 8, 29, 36, 57, 211 and 393 for subjects in all 
five treatment arms.  
Duration of Trial  
Subje cts will be enrolled for approximately 393 days; that is to capture safety information [ADDRESS_275250] trial dose. Short term follow -up for AEs, SAEs, concomitant medications and 
AESI will be 28 days following each dose (Dose 1: through Day 28, col lected on Day 29 and 
Dose 2: through Day 56, collected on Day 57). Final follow -up for SAEs and AESI will be 
performed [ADDRESS_275251] vaccination (i.e., on Day  393).  
A schedule of procedures is listed in Table 2 .  
  
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
125 3DJHRI
6WDWLVWLFDO$QDO\VLV 3ODQ)LQDO )HEUXDU\

7DEOH6FKHGXOHRI7ULDO3URFHGXUHV
3URFHGXUH 'D\
'D\
'D\
'D\
'D\
'D\
'D\
(7O
9LVLW1XPEHU    
9LVLW:LQGRZV  
GD\V
GD\V
GD\V
GD\V
GD\VGD\V
3URFHGXUHV    
6LJQHGLQIRUPHGFRQVHQW ;   
3UHJQDQF\WHVWD ;;   
$VVHVVPHQWRIHOLJLELOLW\FULWHULDE ;;   
'HPRJUDSKLFV ;   
0HGLFDOKLVWRU\ ;   
0HGLFDWLRQKLVWRU\ ;   
&RQFRPLWDQWPHGLFDWLRQV ;;; ; ;; ;
3K\VLFDO([DPLQDWLRQ&RPSOHWHF ;   
6\PSWRP'LUHFWHG ;; ; ;; ;
9LWDO6LJQV ;;; ; ;; ;
+HLJKWZHLJKWDQG%RG\0DVV,QGH[%0, ;   
5DQGRPL]DWLRQ ;   
,QYHVWLJDWLRQDOYDFFLQHDGPLQLVWUDWLRQ ;;   
3RVWYDFFLQDWLRQDVVHVVPHQWG ;;   
'LDU\FDUGHWUDLQLQJDQGKDQGRXWWRWKHVXEMHFW'D\V
'D\V
'D\V
'D\V

'LDU\FDUGHUHYLHZZLWKWKHVXEMHFWDQG
FROOHFWLRQ'D\V
'D\V
'D\V
'D\V

6ROLFLWHG$GYHUVH(YHQWV$(V ;;  
8QVROLFLWHG$(VI;;; ; ; 
6HULRXV$GYHUVH(YHQWV6$(VJ ;;; ; ;; ;
$GYHUVH(YHQWVRI6SHFLDO,QWHUHVW$(6, ;;; ; ;; ;
%ORRG'UDZIRU,PPXQRJHQLFLW\aP/K;L;;L; ;; ;
CCI
CCI
kedon-commercial use only aanand subject to the applicable Terms of UsesssmsGD\VGD\Vrmmm
T
bbbbleabaaaa
plipapapappapeaaa
ta
ttthot;;tooo o
ctj;;jjjebj;;bjbjbjbjsuddddandya nannananananyaa
nD\VV
'D\'nnnlyoneual
erc
mmQWHUHVW$UHVW$om
JHQLFLW\HQLFLc
For noFoFo
eda: Fo
125 3DJHRI
6WDWLVWLFDO$QDO\VLV 3ODQ)LQDO )HEUXDU\

1RWH,IWKHDGPLQLVWUDWLRQRI'RVHLVFKDQJHGZLWKLQWKHDOO RZDEOHZLQGRZVXEVHTXHQWYLVLWVVKRXOGEH
FDOFXODWHGIURPWKH'D\RIWKHVHFRQGGRVHHJLI'RVHLV JLYHQRQWULDO'D\WKHQH[WYLVLWVKRXOGEH
VFKHGXOHGIRUWULDO'D\
)RRWQRWHV
D,QIHPDOHVXEMHFWVRIFKLOGEHDULQ JSRWHQWLDOXULQHSUHJQDQF\W HVWVZLOOEHSHUIRUPHGEHIRUHHDFKYDFFLQDWLRQ
6XEMHFWVZLOOUHFHLYHFRQWLQXHG JXLGDQFHZLWKUHVSHFWWRWKHDY RLGDQFHRISUHJQDQF\DVSDUWRIWKHWULDO
SURFHGXUHV
E&RQWLQXLQJHOLJLELOLW\E\UHYLHZRIUHOHYDQWLQFOXVLRQH[FOXVL RQFULWHULDZLOOEHGRFXPHQWHGEHIRUHHDFK
YDFFLQDWLRQ
F$FRPSOHWHSK\VLFDOH[DPLQDWLRQLVS HUIRUPHGRQ'D\$WRWKHU YLVLWVVXEMHFWVPD\XQGHUJRDEULHI
V\PSWRPGLUHFWHGSK\VLFDOH[DPLQDWLRQDQGLISHUIRUPHGVKRXOG DVVHVVFOLQLFDOO\VLJQLILFDQWFKDQJHVIURP
EDVHOLQH
G$IWHUYDFFLQDWLRQRQ'D\DQG'D\WKHVXEMHFWZLOOEHREVH UYHGIRUDWOHDVWPLQXWHVLQFOXGLQJ
REVHUYDWLRQIRUVROLFLWHG$(VXQ VROLFLWHG$(VDQGERG\WHPSHU DWXUHPHDVXUHPHQW
H'LDU\FDUGVZLOOEHFRPSOHWHGIURP'D\WKURXJK'D\'DLO\ GLDU\RIVROLFLWHG$(VIURP'D\WKURXJK
'D\DQG'D\WKURXJK'D\WKHGD\RIYDFFLQDWLRQDQGIRU GD\VIROORZLQJHDFKYDFFLQDWLRQ
,QIRUPDWLRQDERXWXQVROLFLWHG$(VDQGPHGLFDWLRQVZLOOEHFROOH FWHGIURP'D\WKURXJK'D\
I$(VLQFOXGLQJVROLFLWHGORFDODQG V\VWHPLFHYHQWVDQGXQVROLFLW HG$(VZLOOEHFROOHFWHGZLWKWKHKHOSRIWKH
GLDU\FDUGDQGE\LQWHUYLHZDQG FDWHJRUL]HGE\WKH,QYHVWLJDWRU DVPLOGPRGHUDWHRUVHY HUHDQGUHODWHGQHVVWR
YDFFLQH
J6$(VZLOOEHUHSRUWHGWRWKH6SRQ VRURUWKHLUGHVLJQHHZLWKLQ KRXUVRIWKH,QYHVWLJDWRUEHFRPLQJDZDUHRI
WKHHYHQWWKURXJKRXWWKHWULDO1RWH)RUWKLVWULDO6$(UHSRU WLQJZLOOEHGRQHE\XVH RIWKHHOHFWURQLF&DVH
5HSRUW)RUPH&5),IWKH(OHF WURQLF'DWD&DSWXUH('&V\VWHP LVXQDYDLODEOHDSDSHU6SRQVRU6$(
IRUPSDSHU&5)VKRXOGEHFRPSOHWHGDQGWKHHYHQWPXVWEHHQWHUH GLQWRWKH('&RQFHDFFHVVLVDYDLODEOH
K%ORRGGUDZIRULPPXQRJHQLFLW\LQFOXGHVDQWL QRURYLUXVDQWL 1R9VSHFLILF*,DQG*,,+LVWREO RRG*URXS
$QWLJHQ+%*$EORFNLQJ DVVD\V3DQ,PPXQRJOREXOLQ(Q]\PH OLQNHG,PPXQRVRUEHQW$VVD\3DQ ,J(/,6$
RQ'D\SULRUWRYDFFLQDWLR Q'D\'D\SULRUWRYDFFLQDWLRQ'D\'D\'D\ DQG'D\
,J$(/,6$RQ'D\ SULRUWRYDFFLQDWLRQ'D\ 'D\SULRUWRYDFFLQDWLRQ'D\'D\' D\
'D\DQG+%*$EORFNLQJ DVVD\XVLQJDSDQHORI1R9VWUDLQVQRWUHSUHV HQWHGLQWKHYDFFLQHRQ'D\SULRU
WRYDFFLQDWLRQ'D\'D\DQG'D\*HRPHWULF0HDQ7LW HU*07*HRPHWULF0HDQ%ORFNLQJ7LWHU
*0%7 *HRPHWULF0HDQ)ROG5LVH*0)5 DQGSHUFHQWDJHRIVXEMHFWV ZLWK¬ïIROGDQWLERG\ULVHIURP
EDVHOLQHZL OOEHGHWHUPLQHGIRUDOODYDLODEOH VXEMHFWVLQHDFKDJHJURXS 


L6DPSOHVZLOOEHWDNHQSULRUWRYDFFLQDWLRQ
M

N 


O'D\(7(DUO\7HUPLQDWLRQ,QFDVHRI(DUO\7HUPLQDWLRQVD PHVDIHW\SURFHGXUHVZLOODSSO\5HIHUWR
6HFWLRQVDQG RIWKHSURWRFRO >@
CCI
CCI
CCI
Property of Taked'D\(D\
6HFWLRQ6HFWLRda: For non-commercial use only and subject to the applicable Terms of UseQ
UHHDFKUHHDFK
JRDEULHIJRDEUL
FDQWFKDQQWFKD
PLQXWHVLQXWHVLQL
QWQW
FLWHG$(VWHG$(
OORZLQJHOORZLQJ
P'D\W'D\
VZLOOEHFZLOOEH
PLOGPRGOGPR
QKRXUVKRX
RUWLQJZLUWLQJZ
'&V\VWH&V\V
PXVWEHHXVWEH
RYLUXVDQYLUXV
RJOREXOLQOREXOL
SULRUSULR
Q'D\'D\
VLQJDSDQQJDS
G'D\'D\
)ROG5LVHROG5L
RUDOODYDLDOODY
QSULRUWRSULRUWomco
For non:F oda: keda
NOR -204 Page 14 of 41 
Statistical Analysis Plan ( Final 1 .0) 02 February 2017  
 
5.0 ANALYSIS ENDPOINTS  
5.1 Primary Endpoints  
Immunogenicity  
‚Ä¢ Percentage of subjects with a 4 -fold ri se or greater in serum anti -NoV antibody titers for both 
GI.1 VLP and GII.4 VLP as measured by [CONTACT_228667] (HBGA) blocking  assay 
on Day  57 ([ADDRESS_275252] vaccination).  
Safety  
‚Ä¢ Percentage of subjects with solicited local AEs (pain, eryt hema, induration, and swelling at 
the injection site) for 7  days (the day of vaccination and the following six days) after each 
vaccination;  
‚Ä¢ Percentage of subjects with solicited systemic AEs (headache, fatigue, myalgia, arthralgia, 
vomiting, and diarrhea)  for 7  days after each vaccination;  
‚Ä¢ Percentage of subjects with elevated body temperature ‚â•38¬∞C (defined as fever) for 7 days 
after each vaccination;  
‚Ä¢ Percentage of subjects with any unsolicited AEs from Day 1 through Day 28 (post -
vaccination 1) and from Da y 29 through Day 57 (post -vaccination 2), inclusive;  
‚Ä¢ Percentage of subjects with SAEs throughout the trial.  
5.2 Secondary Endpoints  
Immunogenicity  
HBGA blocking  assay  
‚Ä¢ Percentage of subjects with a 4 -fold rise or greater of serum anti -NoV GI.1 VLP and anti -
NoV GII.4 VLP antibody ti ters as measured by [CONTACT_228668] (Day 8, Day 29, Day 
36, Day  211, and Day  393);  
‚Ä¢ Percentage of subjects with a 4 -fold rise or greater of serum anti -NoV GI.1 VLP antibody  
titers as measured by [CONTACT_228669] (Day 8, Day 29, D ay 36, Day 57, Day  211, and 
Day 393);  
‚Ä¢ Percentage of subjects with a 4 -fold rise or greater of serum anti -NoV GII.4 VLP antibody 
titers as measured by [CONTACT_228668] (Day 8, Day 29, Day 36, Day 57, Day  211, and 
Day 393);  
‚Ä¢ GMT of anti -NoV GI.1 VLP antibody ti ters as measured by [CONTACT_228668] (Day  1, 
Day 8, Day 29, Day 36, Day 57, Day 211, and Day  393);  
‚Ä¢ GMT of anti -NoV GII.4 VLP antibody ti ters as measured by [CONTACT_228668] (Day  1, 
Day 8, Day 29, Day 36, Day 57, Day 211, and Day  393);  
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
125 3DJHRI
6WDWLVWLFDO$QDO\VLV 3ODQ)LQDO )HEUXDU\

x*0)5RIDQWL1R9*,9/3DQWLERG\WLWHUVDVPHDVXUHGE\+%*$E ORFNLQJDVVD\'D\
'D\'D\'D\'D\DQG'D\
x*0)5RIDQWL1R9*,,9/3DQWLERG\WLWHUVDVPHDVXUHGE\+%*$ EORFNLQJDVVD\'D\
'D\'D\'D\'D\DQG'D\
3DQ,J(Q]\PHOLQNHG,PPXQRVRUEHQW$VVD\(/,6$
x3HUFHQWDJHRIVXEMHFWVZLWKD IROGULVHRUJUHDWHURIVHUXPD QWL1R9*,9/3DQGDQWL
1R9*,,9/3DQWLERG\WLWHUVD VPHDVXUHGE\3DQ,J(/,6$'D\ 'D\'D\'D\
'D\DQG'D\
x3HUFHQWDJHRIVXEMHFWVZLWKD IROGULVHRUJUHDWHURIVHUXPD QWL1R9*,9/3DQWLERG\
WLWHUVDVPHDVXUHGE\3DQ,J(/, 6$'D\'D\'D\'D\ 'D\DQG
'D\
x3HUFHQWDJHRIVXEMHFWVZLWKD IROGULVHRUJUHDWHURIVHUXPD QWL1R9*,,9/3DQWLERG\
WLWHUVDVPHDVXUHGE\3DQ,J(/, 6$'D\'D\'D\'D\ 'D\DQG
'D\
x*07RIDQWL1R9*,9/3DQWLERG \WLWHUVDVPHDVXUHGE\3DQ,J (/,6$'D\'D\
'D\'D\'D\'D\DQG'D\
x*07RIDQWL1R9*,,9/3DQWLERG \WLWHUVDVPHDVXUHGE\3DQ,J (/,6$'D\'D\
'D\'D\'D\'D\DQG'D\
x*0)5RIDQWL1R9*,9/3DQWL ERG\WLWHUVDVPHDVXUHGE\3DQ,J (/,6$'D\'D\
'D\'D\'D\DQG'D\
x*0)5RIDQWL1R9*,,9/3DQWL ERG\WLWHUVDVPHDVXUHGE\3DQ, J(/,6$'D\
'D\'D\'D\'D\DQG'D\
6DIHW\
x3HUFHQWDJHRIVXEMHFWVZLWK$(6,WKURXJKRXWWKHWULDO
x3HUFHQWDJHRIVXEMHFWVZLWKDQ \$(OHDGLQJWRVXEMHFW¬∂VZLWKGUD ZDOWKURXJKRXWWKHWULDO
([SORUDWRU\(QGSRLQWV
CCI
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
DQGDQWDQGD
'D\'D\
9*,9/*,9/
'D\'D\
PDQWLDQWL1R1
\'D'
HDVXUHGEDVXUHG

HUVDVPHVDVP
'D\'D\
ERG\WLWHERG\WLW
'D\D\
9/3DQWLE3DQW
'D\'D\
XEMHFWVZEMHFWV
RIVXEMHRIVXEM
[SORUDWR[SORUDW
ty of [COMPANY_005]
125 3DJHRI
6WDWLVWLFDO$QDO\VLV 3ODQ)LQDO )HEUXDU\
CCI
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Userty of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Us
125 3DJHRI
6WDWLVWLFDO$QDO\VLV 3ODQ)LQDO )HEUXDU\
CCI
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Useable Terms of
NOR -204 Page 18 of 41 
Statistical Analysis Plan ( Final 1 .0) 02 February 2017  
 
6.0 DETERMINATION OF SAMPLE SIZE  
This trial is designed to be primarily descriptive. Therefore the sample size was not determined 
based on formal statistical power calculations but rathe r to provide a reasonable clinical database 
to assess safety and immunogenicity in an elderly population.  
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
NOR -204 Page 19 of 41 
Statistical Analysis Plan ( Final 1 .0) 02 February 2017  
 
7.0 METHODS OF ANALYSIS AND PRESENTATION  
7.1 General Principles  
All statistical analyses will be generated using SAS Version 9.2 or higher.  
Immunogenicity and safety endpoints will be summarized descriptively (frequency and percent 
for categorical data; and number of subjects with non -missing observation, mean, standard 
deviation (SD), median, minimum and maximum for continuous data) by [CONTACT_228670], as appropriate. In summary tables for categorical data for which categories are defined on 
the eCRF, all categories will be presented as specified, even if the subject count  within that 
category is zero. For other categorical data (e.g. adverse event s and medications), only categories 
with at least 1 subjec t will be presented.  
In general, summaries and analyses are to be provided by [CONTACT_228671]. The 
following terminology and conventions will be used as applicable.  
Presentation of re sults by [CONTACT_3148], and by [CONTACT_228672] (60 ‚Äì74, 75 ‚Äì84, and 
‚â•85 years), will be provided for:  
‚Ä¢ A1: Arm 1:  NoV GI.1/GII.4 Bivalent VLP Vaccine, Formulation A, 1 -dose regimen (subjects ‚â•60 years).  
‚Ä¢ A2: Arm 2: NoV GI.1/GII.4 Bivalent VLP Vacci ne, Formulation A, 2 -dose regimen (subjects ‚â•60 years).  
‚Ä¢ A3: Arm 3: NoV GI.1/GII.4 Bivalent VLP Vaccine, Formulation B, 1 -dose regimen (subjects ‚â•60 years).  
‚Ä¢ A4: Arm 4: NoV GI.1/GII.4 Bivalent VLP Vaccine, Formulation B, 2 -dose regimen (subjects ‚â•60 years).  
‚Ä¢ A5: Arm 5: NoV GI.1/GII.4 Bivalent VLP Vaccine, Formulation A, 1 -dose regimen (Subjects 18 ‚Äì49 
years).  
When applicable, summaries of all subjects (treatment arms A1, A2, A3, A4  and A5 combined), 
and/or summaries of all elderly subjects (treatment arms A1, A 2, A3, and A4 combined), will be 
provided.  
Unless otherwise stated the conventions below will be used in reporting results. Minimum and 
maximum values will be presented using the same number of decimal places as the recorded 
data. Means, the least squares means (LS Means), and medians will be presented to [ADDRESS_275253] deviations (SD) will be presented to 2 more 
decimal places than the recorded data. The CI about a parameter estimate will be presented using 
the same n umber of decimal places as the parameter estimate (ie., [ADDRESS_275254] than the 
recorded data). Percentages will be presented to [ADDRESS_275255] (e.g., 80.3%). All p -values will 
be rounded to 3 decimal places. If a p -value is less than 0.001, it will  be reported as ‚Äú<0.001‚Äù; if 
a p-value is greater than 0.999, it will be reported as ‚Äú>0.999‚Äù.  
When count data are presented, the percentage will be suppressed when the count is zero in order 
to draw attention to the non -zero counts.  
Baseline is defined as  the last non -missing measurement taken before the first dose of 
vaccination including the screening value or a value from an unscheduled visit, if necessary.  
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
125 3DJHRI
6WDWLVWLFDO$QDO\VLV 3ODQ)LQDO )HEUXDU\

6WXG\'D\DQG$QDO\VLV :LQGRZ'HILQLWLRQV
'HILQLWLRQRI6WXG\'D\V
6WXG\'D\LVGHILQHGWREHW KHGDWHRIWKHILUVWYDFFLQDWLRQ DVUHFRUGHGRQWKH&5)YDFFLQDWLRQ
SDJH6WXG\GD\VZLOOEHGHILQH GUHODWLYHWR'D\,QDGGLWLRQ WKHVWXG\SHULRGZLOOEHEURNHQ
GRZQLQWRWZRSHULRGV)RUSHULRGRQHVWXG\GD\VIROORZLQJWKH ILUVWYDFFLQDWLRQXSXQWLOWKH
GDWHRIWKHVHFRQGYDFFLQDWLRQLQFOXVL YHDUHGHILQHGUHODWLYH WRVWXG\'D\)RUSHULRGWZR
VWXG\GD\VIROORZLQJWKHVHF RQGYDFFLQDWLRQXSXQWLOWKHHQGRI VWXG\YLVLWDUHGHILQHGUHODWLYHWR
WKHGDWHRIWKHVHFRQGYDFFLQDWLRQ
'HILQLWLRQRI6WXG\9LVLW:LQGRZV
$ZLQGRZLQJFRQYHQWLRQZLOOEHXVH GWRGHWHUPLQHWKHDQDO\VLVY DOXHIRUDJLYHQVWXG\YLVLWIRU
REVHUYHGGDWDDQDO\VHV 7KHZLQGRZGHILQLWLRQVDVRXWOLQHGEHO RZLQ7DEOHZLOOEHXVHGIRU
WKHLPPXQRJHQLFLW\ DQGYLWDOVLJQVUHVSHFWLYHO\ 7KH
ZLQGRZVIRULPPXQRJHQLFLW\DQGYLWDOVL JQVDUHFRQVWUXFWHGUHOD WLYHWRDFWXDOGRVLQJGD\7KH
ZLQGRZFRQYHQWLRQVDUH 
$ZLQGRZRIGD\VIURPWKHWDUJHWGD\DUHDSSOLHGWR6WXG\ 9LVLWVDQG
$ZLQGRZRIGD\VIURPWKHWDUJH WGD\DUHDSSOLHGWR6WXG\ 9LVLWVDQG
$ZLQGRZRIGD\VIURPWKHWDU JHWGD\DUHDSSOLHGWR6WXG \9LVLWVDQG
7DEOH DQG6DIHW\$QDO\VHV 
    9LVLW:LQGRZ6WXG\'D\
3HULRG9LVLW
1XPEHU9LVLW
1DPH'D\5HODWLYHWR
'RVHZLWKLQWKH3HULRG
E6HURORJ\ 9LWDO6LJQV
3HULRG
5HODWLYHWR'RVH%DVHOLQHD   
'D\  ¬± QD ¬±
'D\  ¬± QD ¬±
3HULRG
5HODWLYHWR'RVH'D\  ¬± ¬± ¬±
'D\  ¬± ¬± ¬±
'D\  ¬± QD ¬±
'D\  ¬± ¬± ¬±
)RRWQRWHV
D:KHUHWLPHLVDYDLODEOHWKHWLP HRIWKHFROOHFWLRQQHHGVWREH SULRUWRWKHILUVWGRVHRIYDFFLQDWLRQ'D\
REVHUYDWLRQVWDNHQDIWHUWKHILUV WGRVHDUHFRQVLGHUHGSRVWEDV HOLQHYDOXHV
E)RUHDFKSHULRGWKHDGPLQLVWU DWLRQRIWKHYDFFLQDWLRQLVGHVLJ QDWHGDV6WXG\'D\)RUDQDO\VHVZLWKLQD
SHULRGWKHVWXG\GD\YDOXHLVLQFUHPHQWHGE\IRUHDFKGDWHI ROORZLQJWKHYDFFLQHDGPLQLVWUDWLRQ
2QHRUPRUHUHVXOWVIRUDSDUWLFXODULPPXQRJHQLFLW\RUYLWDOVL JQYDULDEOHPD\EHREWDLQHGLQWKH
VDPHYLVLWZLQGRZVHHVWXG\ZLQGRZGHILQLWLRQVLQ 7DEOH,QVXFKDQHYHQWWKHUHVXOWZLWKCCI
CCI
CCI
Property of [COMPANY_005]: For non'D\'D\n-commercial use 'D\5HODWD\5HOD
'RVHZ'RVHZ
3HULR3HUal
mOLQHQHDDmmmmm
'D\\o
nno'nnnn
Foaaa:dadd
Tad
RRWQRWHVRRWQRWHonly and subject to the applicable Terms of UseRQ
HQ
WKHWKH
GWZRWZR
HGUHODWLGUHOD
UDJLYHQUDJLYH
7DEOHDEOH
LJQVUHVLJQVU
DWLYHWRDWLYHW
SSOLHGWRSSOLHGW
UHDSSOLHHDSSO
GD\DUHGD\DUH
DD:K
Ee o
125 3DJHRI
6WDWLVWLFDO$QDO\VLV 3ODQ)LQDO )HEUXDU\

WKHGDWHFORVHVWWRWKHH[SHFWHGYLVLWGDWHZLOOEHXVHG,QW KHHYHQWWKDWREVHUYDWLRQVDUH
HTXLGLVWDQWIURPWKHH[SHFWHGYLVL WGDWHWKHODWHUREVHUYDWLRQ ZLOOEHXVHG
,QDGGLWLRQWKHIROORZLQJUXOHVZLOO EHXWLOL]HGWRLGHQWLI\WK HUHOHYDQWUHFRUGWREHXVHGIRU
LPPXQRJHQLFLW\DQDO\VLVRIJHQRW\SHSDUDPHWHUV *,9/3DQG*,,9/3 7KHVHUXOHVDUH
DSSOLFDEOHWRDOOLPPXQRJHQLFLW\ HQGSRLQWVGHVFULEHGLQ6HFWLRQ 
7KHUXOHVDUHWREHDSSOLHGLQWKHIROORZLQJ
RUGHU
,IWKHFROOHFWLRQGDWDDWFORVHVWYLVLWZLQGRZKDYHERWK*,D QG*,,QRQPLVVLQJ
PHDVXUHPHQWVXVHWKDWFROOHFWLRQGDWD
,IWKHFROOHFWLRQGDWDDWFORVHVWYL VLWZLQGRZKDYHHLWKHU*, RU*,,PHDVXUHPHQW
PLVVLQJEXWGDWDFROOHFWHGDWRW KHUGDWHWLPHZLWKLQWKHVDPH YLVLWZLQGRZKDYHERWK
*,DQG*,,PHDVXUHPHQWVQRQPLVVLQJXVHWKHFROOHFWLRQGDW DZLWKERWK*,DQG
*,,QRQPLVVLQJ
,IQRQHRIGDWDFROOHFWHG ZLWKLQDYLVLWZLQGRZKDYHERWK*, DQG*,,QRQPLVVLQJ
SLFNWKH*,DQG*,,QRQPLVVLQJPHDVXUHPHQWVHSDUDWHO\EDVH GRQ6$3VHOHFWLRQ
UXOH7KDWLVWKHDQDO\VLVIODJD VVLJQHGWR*,DQG*,,ZLO OKDYHGLIIHUHQWFROOHFWLRQ
GDWHWLPH
,IRQO\RQHRIWKHJHQRW\SHSDUD PHWHUKDVQRQPLVVLQJPHDVXUHPH QWVZLWKLQDYLVLW
ZLQGRZWKHDQDO\VLVIODJZLOORQO\D SSO\WRWKHSDUDPHWHU*, RU*,,ZLWKQRQ
PLVVLQJPHDVXUHPHQWV
'DWDVHOHFWHGLQSRLQWZLOOEHLQFOXGHGLQVX[COMPANY_003]U\DQDO\VLVR I¬≥! IROGULVHIRUERWK
*,DQG*,,¬¥HQGSRLQWV
'LDU\GDWDLQFOXGLQJUHDFWRJHQLFLW \DQGRUDOERG\WHPSHUDWXUH DUHFROOHFWHGDWWKHVWXG\YLVLWV
DQGZLOOFRQWDLQHQWULHVE\GDWH ZLWKLQWKHLQWHUYDOEHWZHHQWK HYLVLWV9LVLWZLQGRZUXOHVZLOOQRW
EHDSSOLHGWRWKHGLDU\GDWDDQGZLOO EHVX[COMPANY_003]UL]HGE\WKHQRP LQDOGD\VDVUHFRUGHGRQWKH
&5)
$OOGDWDLQWKHFOLQLFDOGDWDED VHZLOOEHSURYLGHGLQWKHOLVWL QJVDWILQDODQDO\VLVLH'D\
$QDO\VLVLQFOXGLQJWKRVHFROOHFWHGEH\RQGWKHFXWRIIHJGD WDFROOHFWHGDIWHU'D\IRU'D\
DQDO\VLV
&RQYHQWLRQVIRU+DQGOLQJ 0LVVLQJ9DOXHV
7KHUHZLOOEHQRLPSXWDWLRQIRUPLVVLQJ GDWDZLWKWKHH[FHSWLRQ RIPLVVLQJRUSDUWLDOGDWHV
LHVWDUWGDWHVRI$( VDQGWLWHUYDOX HVPHDVXUHGEHORZ ORZHUOLPLWRITXDQWLILFDWLRQ
//R4RUDERYHXSSHUOLPLW RITXDQWLILFDWLRQ8/R4
0LVVLQJRUSDUWLDO$(GDWHV
3DUWLDOGDWHVZLOOEHSUHVHQWHGDVU HFRUGHGLQWKHOLVWLQJV7K HSDUWLDOGD WHVRI$(VZLOOEH
LPSXWHGRQO\WRGHWHUPLQHWKHUHODWLRQVKLSEHWZHHQWKHVWDUWGD WHRIWKRVHSDUWLDOGDWHVDQGWKH
GRVHGDWHRIWKHPRVWDSSURSULDWH YDFFLQDWLRQWKDWWKH$(VKRXO GEHDVVRFLDWHGZLWKLH
9DFFLQDWLRQRU9DFFLQDWLRQCCI
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of UseOORZLQJRZLQ
QPLVVLQQPLVVL
,PHDPHD
LVLWZLQGVLWZLQ
QGDWDZQGDWDZ
RWK*,WK*
VHSDUDWHHSDUDWH
DQG*,,QG*,
VQRQQRQP
SO\WRWKO\WRWK
LQFOXGHLQFOXG
QLFLW\DQLFLW\D
GDWHZLWKDWHZL
DWDDQGWDDQG
QLFDOGDWFDOG
XGLQJWKXGLQJW
V
&RQYH&RQY
KHUHZLOOKHUHZL
LHVWDLHV
//R//
0
NOR -204 Page 22 of 41 
Statistical Analysis Plan ( Final 1 .0) [ADDRESS_275256] vaccination. In the above example if an event is known to start 
in 2016 (day and month missing) and the end date is known as 20 March 2016, then an imputed 
start date of 02 March (date of Vaccination 2) will be used. If an event is missing both start and 
end date then the last vaccination date will be used as the imputed start date. When event end 
dates are missing or partially missing, information such as whether the AEs are ongoing by [CONTACT_228673].  
Titer measured below LLoQ or above ULoQ  
For a titer value measured as having a value below LLoQ, it is to be imputed as  the half of the 
LLoQ in summaries and analyses, and it will be listed as reported in the raw data. For example, 
if an assay has the level of LLoQ of 120, and a sample is reported to have ‚Äú<120‚Äù as the titer 
level, a value of 60 (half of 120) is to be used  for the statistical summaries.  
For a titer value measured as having a value above ULoQ, a value of the level of ULoQ will be 
used for the summaries and analyses, and it will be listed as reported in the raw data. For 
example, if an assay has the level of  ULoQ of 120, and a sample is reported to have ‚Äú>120‚Äù as 
the titer level, a value of 120 is to be used for the statistical summaries.  
7.2 Analysis Sets  
The following analysis sets are defined for this study.  
Randomized Set : all randomized subjects regardless of whether any study vaccine (NoV VLP 
vaccine or placebo) was received. Data will be analyzed according to treatment randomized.  
Note that subjects who were randomized in error (per IWRS) will be excluded from the 
Randomized Set.  
Safety Analysis Set (SAF) : all subjects who receive at least 1 dose of vaccine (NoV VLP vaccine 
or placebo). Data will be analyzed according to treatment received.  
Full Analysis Set (FAS):  all subjects who are randomized and have at least 1 dose of vaccine 
(NoV VLP vaccine or place bo). Data will be analyzed according to treatment randomized.  
Per Protocol Set (PPS) : All subjects in the FAS, who receive the planned vaccination (both 
doses of vaccine, i.e. NoV VLP vaccine or placebo), and do not have major protocol violations 
will be i ncluded in the PPS. The categories o f major protocol violations include:  
1) Not meeting entry criteria, based on selected inclusion/exclusion criteria (exclusion 
criteria #10 and #11) defined in protocol [ 1, 2] Sections 7.1 and 7.2;  
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
NOR -204 Page 23 of 41 
Statistical Analysis Plan ( Final 1 .0) 02 February 2017  
 
Exclusion criterion #10:  Known or suspected impairment/alteration of imm une function, 
including the following:  
a. Chronic use of oral steroids (Equivalent to 20 mg/day prednisone ‚â• 12 weeks / ‚â• 
2 mg/kg body weight / day prednisone ‚â• 2 weeks) within 60 days prior to Day 1 
(use of inhaled, intranasal, or topi[INVESTIGATOR_177804]).  
b. Receipt of parenteral steroids (Equivalent to 20 mg/day prednisone ‚â• 12 weeks / ‚â• 
2 mg/kg body weight / day prednisone ‚â• 2 weeks) within 60 days prior to Day 1.  
c. Receipt of immunosuppressive therapy within 3 months prior to Day 1.  
d. Receipt of immun ostimulants within 60 days prior to Day 1.  
e. Receipt of parenteral, epi[INVESTIGATOR_177805] -articular immunoglobulin preparation, 
blood products, and/or plasma derivatives within 3 months prior to Day 1 or 
planned during the full length of the trial.  
f. Human Immunod eficiency Virus (HIV) infection or HIV -related disease.  
g. Genetic immunodeficiency.  
           Exclusion criterion #11:  Abnormalities of splenic or thymic function.  
2) Receiving wrong trial treatment;  
3) Not receiving both doses of trial vaccine or receiving the s econd trial dose inadmissibly 
outside of the visit window;  
4) Receiving prohibited therapi[INVESTIGATOR_228657] (also specified in protocol [ 1, 
2] Section 9.1.2):  
‚Ä¢ Parenteral immunoglobulin preparation, blood products, and/or plasma 
derivatives within [ADDRESS_275257] vaccination, or any time during the trial.  
‚Ä¢ Immun osuppressive therapy within 6 months or systemic (eg, oral or parenteral) 
corticosteroid treatment within 60 days prior to vaccine administration.  
‚Ä¢ Administration of other vaccines within 14 days (for inactivated vaccines) or 28 
days (for live vacci nes) pri or to administration of study vaccine . 
5) Other major violations  that compromise the primary immunogenicity endpoint 
assessment .  
A major protocol violation is defined as a protocol deviation that is considered to have a 
significant impact on the immunogenici ty results of the subject. All protocol deviations will be 
identified prior to unblinding and a clinical judgment will be necessary to classify each deviation 
as a "major" violation or not.  These violations and the judgment regarding their use will be 
listed and summarized in the final clinical study report. Refer to Section 7.3.[ADDRESS_275258] completed the Day 57 Visit ([ADDRESS_275259] 
vaccination). Refer to Section 7.12. 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
125 3DJHRI
6WDWLVWLFDO$QDO\VLV 3ODQ)LQDO )HEUXDU\

7KHVDIHW\DQDO\VLVZLOOEHED VHGRQWKH6DIHW\$QDO\VLV6HW7 KHSULPDU\LPPXQRJHQLFLW\
DQDO\VHVZLOOEHEDVHGRQWKH33 6DQGDGGLWLRQDOLPPXQRJHQLFLW \DQDO\VHVZLOOEHEDVHGRQWK H
)$6 



'LVSRVLWLRQRI6XEMHFWV
'LVSRVLWLRQ
7KHQXPEHURIVFUHHQIDLOXUHVWKHLUF KDUDFWHULVWLFVDQGWKHSU LPDU\UHDVRQVIRUVFUHHQIDLOXUH
ZLOOEHVX[COMPANY_003]UL]HGRYHUDOO
'LVSRVLWLRQRIDOOVFUHHQHGVXEM HFWVZLOOEHVX[COMPANY_003]UL]HGGHVFULS WLYHO\LQFOXGLQJDVX[COMPANY_003]U\RI
WKHQXPEHURIVFUHHQHGVXEMHFWVWKHQXPEHURIUDQGRPL]HGVXEMH FWVDQGWKHQXPEHURIQRQ
UDQGRPL]HGVXEMHFWVIRUHDFKDJHJ URXSDOOHOGHUO\VXEMHFWVDQ GDOOVXEMHFWVRYHUDOO
7KHQXPEHURIUDQGRPL]HGVXEMHFWVZLOODOVREHSUHVHQWHGE\WUH DWPHQWDUPDOOHOGHUO\VXEMHFWV
DQGDOOVXEMHFWVRYHUDOOIRUHDFK FRXQWU\FHQWHUDQGDJHJURXS ,QDGGLWLRQDQDO\VLVSRSXODWLRQV
ZLOOEHVX[COMPANY_003]UL]HGE\WUHDWPHQWDUPDOOHOGHUO\VXEMHFWVDQGD OOVXEMHFWVRYHUDOOIRUDOODJH
JURXSVDQGE\WUHDWPHQWDUPDQGD OOHOGHUO\VXEMHFWVZLWKLQDJH JURXSV
'LVSRVLWLRQIRUDOOUDQGRPL]HGVXEMHF WVZLOOEHVX[COMPANY_003]UL]HGE\W UHDWPHQWDUPDOOHOGHUO\VXEMHFWV
DQGDOOVXEMHFWVRYHUDOOIRUDOOD JHJURXSVDQGE\WUHDWPHQWDU PDQGDOOHOGHUO\VXEMHFWVZLWKLQ
DJHJURXSV'LVSRVLWLRQFDWHJRULHVLQFOXGH
x1XPEHURIUDQGRPL]HGVXEMHFWVDQGQXPEH URIUDQGRPL]HGVXEMHFWV EXWQRWGRVHG
x1XPEHURIVXEMHFWVFRPSOHWLQJWKHYDFFLQHUHJLPHQVWXG\YLVLWV 
x1XPEHURIVXEMHFWVZKRSUHPDWXUHO\GLVFRQWLQXHGWKHYDFFLQHUHJ LPHQVWXG\YLVLWV
x3ULPDU\UHDVRQIRUSUHPDWXUH GLVFRQWLQXDWLRQRIW KHYDFFLQHUHJ LPHQVWXG\YLVLWV
,QGLYLGXDOVXEMHFWGLVSRVLWL RQGDWDZLOOEHSURYLGHGLQOLVWLQJ V
)RU'0&DQG,$WKHQXPEHURIRQJRLQJVXEMHFWVWKDWKDYHQRW\HW FRPSOHWHGWKHYDFFLQH
UHJLPHQVWXG\YLVLWVZLOODOVREHSURYLGHG
3URWRFRO9LRODWLRQV
0DMRUSURWRFROYLRODWLRQVOHDGLQJWR H[FOXVLRQIURP336ZLOOEH VX[COMPANY_003]UL]HGE\WUHDWPHQWDUP
DOOHOGHUO\VXEMHFWVDQGDOOVXEM HFWVRYHUDOOIRUDOODJHJURX SVDQGE\WUHDWPHQWDUPDQGDOO
HOGHUO\VXEMHFWVZLWKLQDJH JURXSVEDVHGRQ)$6$OOSURWRFROG HYLDWLRQVZLOOEHOLVWHGDQGWKRVH
FRQVLGHUHGDVVLJQLILFDQW SURWRFROGHYLDWLRQDQGD OVRPDMRUSUR WRFROYLRODWLRQVZLOOEHLGHQWLILHG
LQWKHOLVWLQJ)RUGHILQLWLRQRIPDMRUSURWRFROYLRODWLRQVLQ UHODWLRQWRWKLVVWXG\336SOHDVHUHIHU
WR6HFWLRQ CCI
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of UseVIRUVFUIRUVF
O\\LQFOXLQ
HFWVDQGFWVDQ
QGDOOVXQGDOOV
GE\WUHDE\WUH
HJURXSJURXS
EMHFWVDQHFWV
HFWVZLWKFWVZL
EHVXPPVXP
DQGE\WQGE
OXGHXGH
EMHFWVDQHFWVD
PSOHWLQJPSOHWLQ
WVZKRSZKR
QIRUSUHIRUS
WGLVSRVLGLVSR
G,$WKHG,$WK
XG\YLVLG\YL
3URWR3URW
0DMRUSUR0DMRUS
DOOHOGDOO
HOGHOG
125 3DJHRI
6WDWLVWLFDO$QDO\VLV 3ODQ)LQDO )HEUXDU\

'HPRJUDSKLFDQG2WKHU %DVHOLQH&KDUDFWHULVWLFV
$JHJHQGHUUDFHZHLJKWKHLJKW%0,DQGRWKHUEDVHOL QHFKDUDFWHULVW LFVZLOOEHVX[COMPANY_003]UL]HG
GHVFULSWLYHO\E\WUHDWPHQWDU PDQGDOOHOGHUO\VXEMHFWVIRUDO ODJHJURXSVFRPELQHGDQGZLWKLQ
DJHJURXSVEDVHGRQWKHVHWRIDOOUDQGRPL]HGVXEMHFWV7KLVDQ DO\VLVZLOODOVREHUHSHDWHGIRUWKH
336 
7KHVHGDWDZLOODOVREHOLVWHG
0HGLFDO+LVWRU\DQG&RQFXUU HQW0HGLFDO&RQGLWLRQV
0HGLFDOKLVWRU\DQGFRQFXUU HQWPHGLFDOFRQGLWLRQVZLOOEHFRGHG XVLQJWKH0HGLFDO'LFWLRQDU\
IRU'UXJ5HJXODWRU\$FWLYLW LHV0HG'5$9HUVLRQRUKLJKHU FRGLQJV\VWHP
)UHTXHQF\DQGSHUFHQWDJHVRIVXEMHFWVE\PHGLFDOKLVWRU\DQGFR QFXUUHQWPHGLFDOFRQGLWLRQVZLOO
EHVX[COMPANY_003]UL]HGE\V\VWHPRUJDQ FODVV62&SUHIHUUHGWHUP37 DQGE\WUHDWPHQWDUPDQGDOO
HOGHUO\VXEMHFWVIRUDOODJH JURXSVDQGZLWKLQDJHJURXSVEDVH GRQWKH6$)
0HGLFDOKLVWRU\DQGFRQFXUU HQWPHGLFDOFRQGLWLRQGDWDZLOODOVR EHOLVWHG
0HGLFDWLRQ+LVWRU\DQG&RQFRPLWDQW0HGLFDWLRQV
0HGLFDWLRQKLVWRU\DQGFRQFRPLWDQWPHGLFDWLRQVZLOOEHFRGHGXV LQJWKH:RUOG+HDOWK
2UJDQL]DWLRQ'58*GLFWLRQDU\:+2 'UXJ9HUVLRQ0DUFK
)UHTXHQF\DQGSHUFHQWDJHVRIVXEMHFWVE\PHGLFDWLRQKLVWRU\DQG FRQFRPLWDQWPHGLFDWLRQVZLOO
EHVX[COMPANY_003]UL]HGE\SUHIHUUHGPHGLFDWLRQQDPHLHJHQHULFE\W UHDWPHQWDUPDQGDOOHOGHUO\
VXEMHFWVIRUDOODJHJURXSVF RPELQHGDQGZLWKLQDJHJURXSVEDV HGRQWKH6$)
/LVWLQJVIRUPHGLFDWLRQKLVWRU\DQGFRQFRPLWDQWPHGLFDWLRQVZLO ODOVREHSURGXFHG
6WXG\'UXJ([SRVXUHDQG&RPSOLDQFH
&RPSOLDQFHUDWHZLOOEHVX[COMPANY_003]UL] HGE\WUHDWPHQWDUPDQGDOOHOG HUO\VXEMHFWVIRUDOODJHJURXSV
FRPELQHGDQGZLWKLQDJHJURXSVE\SU HVHQWLQJWKHQXPEHUDQGSH UFHQWDJHRIVXEMHFWVUHFHLYLQJ
WKHILUVWGRVHRQO\DQGWKHQXPEHU DQGSHUFHQWDJHRIWKRVHUHF HLYLQJERWKGRVHVRIYDFFLQDWLRQ
7KHGXUDWLRQRIIROORZXSZLOOEHVX[COMPANY_003]UL]HGDVDFRQWLQXRXVYD ULDEOHDQGDOVRDFFRUGLQJWRWKH
IROORZLQJFDWHJRULHV
x¬±GD\V
x¬±GD\V
x¬±GD\V
x¬±GD\V
x! GD\V
7KHIROORZXSLVGHILQHGDVWKHQXPEHURIGD\VVLQFHWKHILUVW YDFFLQDWLRQWRWKHHQGRIVWXG\YLVLW
)RULQWHULPDQDO\VLVDQGVDIHW\UHYLHZLIWKHHQGRIVWXG\YLV LWGDWHVDUHQRWUHSRUWHGWKHVXEMHFW
VSHFLILFGDWHRIGDWDFXWRIIZLOOEHXVHGIRUFDOFXODWLRQ CCI
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of UseWKHKH
0HGLFDO'GLFDO
JV\VWHPV\VWHP
UHQWPHGQWPH
DQGGE\WUE\
RQWKH6QWKH6
DOVREHOOVREH
DWLRQVLRQV
ZLOOEHFROOEHF
UVLRQ0DVLRQ0
PHGLFDWLRHGLFDWL
QDPHLHDPH
DQGZLWKQGZL
GFRQFRPFRQFR
UHDQG&HDQG
VX[COMPANY_003]UXPP
DJHJURXJHJUR
DQGWKHDQGWK
IROORZIROOR
DWHJRULHVJRULH
NOR -204 Page 26 of 41 
Statistical Analysis Plan ( Final 1 .0) 02 February 2017  
 
The analyses described above will be based on SAF. All data will be presented in listings as 
well.  
7.8 Immunogenicity  Analysis  
Immunogenicity analyses will be based primarily on PPS. Supportive immunogenicity analyses 
will be performed using FAS.  
Immunogenicity re sults from the trial will be summarized by [CONTACT_3148] ( A1, A2, A3, A4 and 
A5), and by [CONTACT_228672]. Treatment arm A5 will be presented as reference, 
in each age group level analysis. In addition, for primary and secondary immunogenicity 
endpoints only, results will be summarized by [CONTACT_228674] (over all age groups and within 
each age group), where ‚Äò1 -Dose‚Äô groupi[INVESTIGATOR_228658] A1 and A3 
(i.e. one dose regimen treatment arms) and ‚Äò2 -Dose‚Äô groupi[INVESTIGATOR_228659] e results over 
treatments A2 and A4 (i.e. two dose regimen treatment arms). Finally, for primary and secondary 
immunogenicity endpoints only, results will be summarized by [CONTACT_228675] (over all age 
groups and within each age group), where ‚ÄòMPL -‚Äô group ing will summarize results over 
treatments A1 and A2 (i.e. formula tion A treatment arms) and ‚ÄòMPL+ ‚Äô groupi[INVESTIGATOR_228660] A3 and A4 (i.e. formulation B treatment arms).  
Where comparisons between treatment groups are to be performed, the following pre-specified 
pairwise comparisons of interest will be presented:  
a. A2 vs A1; A3 vs A1; A4 vs A1;   
b. A3 vs A2; A4 vs A2; A4 vs A3;  
c. A1 vs A5; A2 vs A5; A3 vs A5; A4 vs A5;  
d. 1-Dose (A 1 + A3) vs 2 -Dose (A2 + A4).  
e. MPL - (A1 + A2) vs MPL+  (A3 + A4).  
7.8.1 Primary Efficacy Endpoint(s)  
The primary immunogenicity endpoint is defined in Section 5.1. 
The prim ary endpoint will be presented by [CONTACT_228676], as well as by [CONTACT_228674], as described in Section 7.8, at Day [ADDRESS_275260] (i) the fold rise ( fi) in titer value, at a specific post baseline time point is 
calculated as :  
f i = v post/vpre 
where vpost is the post vaccination value of the titer at that specific time point and v pre is the pre 
vaccination (baseline) value of the titer. Subjects with a 4 -fold rise or greater (i.e  f i >= 4) in 
serum anti -NoV antibody titers for both GI.1 VLP and GII.4  VLP as measured by [CONTACT_228677] 57 ([ADDRESS_275261] vaccination)  will be counted within each 
treatment arm at the visit and rates and percentages will be provided based on the number of 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
NOR -204 Page 27 of 41 
Statistical Analysis Plan ( Final 1 .0) 02 February 2017  
 
subjects with a non -missing value within the treatment arm at the visit as well as the 
corresponding 95% CI. The exact (Clopper -Pearso n) method will be used to produce the 95% CI, 
i.e. no adjustment related to age stratification will be applied.  
In addition, pairwise comparisons with lower level as a reference group, as defined in Section 
7.8, will be presented for Day 57, without multiplicity adjustment.   
Risk ratios, and corresponding 95% CIs and Fisher‚Äôs exact test p -values, will be calculated as 
well as risk differences and associated confiden ce limits based on the Newcombe score method 
for pairwise comparisons (a, b, c and d) between treatment arms, within each elderly age group 
(60‚Äì74, 75 ‚Äì84, and ‚â•85 years).   
For between treatment arms analyses for all elderly age groups combined (60 ‚Äì74, 75 ‚Äì84, and 
‚â•85 years), pairwise comparisons (a, b, c and d) will be performed as well. For pairwise 
comparisons ‚Äò a‚Äô, ‚Äòb‚Äô, ‚Äòd‚Äô and ‚Äòe‚Äô only , a Cochran Mantel Haenzel (CMH) method stratified by 
[CONTACT_654], will be used to provide the age adjusted risk ratios, the corr esponding 95% CIs and p -values. 
In addition age adjusted risk differences and corresponding 95% Wald -type CIs will be provided 
(due to computational simplicity) using a CMH weighting strategy. For pairwise comparisons 
‚Äòc‚Äô, a simple non stratified approach will be followed similar to the one described in the previous 
paragraph. Since elderly population treatment arms A1, A2, A3  and A4 do not share the same 
age stratification as the younger adults treatment arm A5, crude estimates for rates and 
proportions fo r treatment arms A1, A2, A3  and A4 will be utilized when comparing these with 
treatment arm A5. 
Since the missing data resulting from dropouts in vaccine trials are typi[INVESTIGATOR_228661] (MCAR) [ 4], a simple way of handling missing data is to use a ‚Äúcomplete case 
analysis‚Äù, i.e., to exclude subjects with missing data at baseline or at the endpoint visit.  In the 
case when more than 20% of the subjec ts have missing data in primary immunogenicity 
endpoint, multiple imputation methods may be explored as a sensitivity analysis.  
7.8.2 Secondary Efficacy Endpoint(s)  
Secondary immunogenicity endpoints are listed in Section 5.2.  
Endpoints listed below, corresponding to percentages of subjects with a 4 -fold rise or greater of 
serum anti -NoV antibody titers for GI.1 VLP and GII.4 VLP separately or both GI.1 VLP and 
GII.4 VLP  simultaneo usly as measured by [CONTACT_228678]-Ig Enzyme -linked 
Immunosorbent Assay (ELISA), will be summarized for study visits Day 8, Day 29, Day 36, 
Day 57, Day 211, and Day  393, following a similar approach to that described in Section 7.8.1  
for the primary endpoint.  Any pairwise comparisons, with lower level as a reference group, as 
defined in Section 7.8, are to be presented for Day 36, Day 57, Day 211, and Day  393 only . 
In addition, percentages of subjects with a 4 -fold rise or greater and corresponding 95% CI will 
be graphically summarized using bar charts, by [CONTACT_228679] 8, Day 29, Day 36, Day 57, Day 211 and Day 393.  
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
NOR -204 Page 28 of 41 
Statistical Analysis Plan ( Final 1 .0) 02 February 2017  
 
HBGA blocking  assay  
‚Ä¢ Percentage of subjects with a 4 -fold rise or greater of serum anti -NoV GI.1 VLP and 
GII.4 VLP antibody titers as measured by [CONTACT_228668] (Day 8, Day 29, Day 
36, Day  211, and Day  393);  
‚Ä¢ Percentage of subjects with a 4 -fold rise or greater of serum anti -NoV GI.1 VLP antibody 
titers as measured by [CONTACT_228668] (Day 8, Day 29, Day 36, Day 57, Day  211, 
and Day  393);  
‚Ä¢ Percentage of subjects with a 4 -fold rise or greater of serum anti -NoV GII.4 VLP 
antibody ti ters as measured by [CONTACT_228668] (Day 8, Day 29, Day 36, Day 57, 
Day 211, and Day  393);  
Pan-Ig Enzyme -linked Immunosorbent Assay (ELISA)  
‚Ä¢ Percentage of subjects with a 4 -fold rise or greater of serum anti -NoV GI.1 VLP and 
GII.4 VLP antibody titers as measured by [CONTACT_228680] -Ig ELISA (Day 8, Day 29, Day 36, Day 
57, Day  211, and Day  393);  
‚Ä¢ Percentage of subjects with a 4 -fold rise or greater of serum a nti-NoV GI.1 VLP antibody 
titers as measured by [CONTACT_228680] -Ig ELISA (Day 8, Day 29, Day 36, Day 57, Day 211, and 
Day 393);  
‚Ä¢ Percentage of subjects with a 4 -fold rise or greater of serum anti -NoV GII.4 VLP 
antibody titers as measured by [CONTACT_228680] -Ig ELISA (Day 8, Day 29,  Day 36, Day 57, Day 211, 
and Day  393);  
Continuous endpoints listed below, corresponding to values of serum anti -NOV antibody titers 
for GI.1 VLP or GII.4 VLP separa tely as measured by [CONTACT_228678]-Ig Enzyme -
linked Immunosorbent Assay (ELISA) , will be summarized and provided in the following way. 
Geometric mean titers (GMT) and the corresponding geometric standard deviation (GSD), and 
95% CIs for the GMT as well as the minimum and maximum titer value, will be presented at 
first instance by [INVESTIGATOR_228033], and by [CONTACT_228681] , as well as by [CONTACT_228682] . Treatment arm A5 will be presented as reference, in each age group level analysis.  
Similarly estimates of Geometric Mean Fold Rise (GMFR) and the corresponding geometric 
standard deviation (GSD), and 95% CIs for the GMFR as well as the minimum and maximum 
fold rise value, will be presented following the same approach as the GMT results.  
In addition, Geometric Mean Anti-NoV Antibody Titers and Geometric Mean  Fold Rise  in Anti -
Nov Antibody Titers  will be graphi cally summarized using bar charts , by [CONTACT_228683] 1, Day 8, Day 29, Day 36, Day 57, 
Day 211 and Day 393 respectively.  
HBGA blocking  assay  
‚Ä¢ GMT o f anti -NoV GI.1 VLP antibody ti ters as measured by [CONTACT_228668] 
(Day  1, Day 8, Day 29, Day 36, Day 57, Day 211, and Day  393);  
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
NOR -204 Page 29 of 41 
Statistical Analysis Plan ( Final 1 .0) 02 February 2017  
 
‚Ä¢ GMT of anti -NoV GII.4 VLP antibody ti ters as measured by [CONTACT_228668] 
(Day  1, Day 8, Day 29, Day 36, Day 57, Day 211 , and Day  393);  
‚Ä¢ GMFR of anti -NoV GI.1 VLP antibody ti ters as measured by [CONTACT_228668] 
(Day  8, Day 29, Day 36, Day 57, Day 211, and Day  393);  
‚Ä¢ GMFR of anti -NoV GII.4 VLP antibody ti ters as measured by [CONTACT_228668] 
(Day  8, Day 29, Day 36, Day 57 , Day 211, and Day  393).  
Pan-Ig Enzyme -linked Immunosorbent Assay (ELISA)  
‚Ä¢ GMT of anti -NoV GI.1 VLP antibody titers as measured by [CONTACT_228680] -Ig ELISA ( Day 1, 
Day 8, Day 29, Day 36, Day 57, Day 211, and Day 393); 
‚Ä¢ GMT of anti -NoV GII.4 VLP antibody titers as measured by [CONTACT_228680] -Ig ELISA ( Day 1, 
Day 8, Day 29, Day 36, Day 57, Day 211, and Day 393); 
‚Ä¢ GMFR of anti -NoV GI.1 VLP antibody titers as measured by [CONTACT_228680] -Ig ELISA (Day 8, 
Day 29, Day 36, Day 57, Day 211, and Day  393);  
‚Ä¢ GMFR of anti -NoV GII.4 VLP antibody titers a s measured by [CONTACT_228680] -Ig ELISA (Day 8, 
Day 29, Day 36, Day 57, Day 211, and Day  393).  
The GMT will be calculated as the anti -logarithm of the mean of the log -transformed titer values 
vi, i.e., anti-logarithm of ‚àë(log transformed titer/n),  where n is the number  of subjects with non 
missing titer information. Similarly the GSD for GMT will be calculated as the anti -logarithm 
transformation of the standard deviation of the log -transformed titer. The 95% CI will be 
calculated as the anti -logarithm transformation of  the upper and lower limits for a two -sided CI 
for the mean of the log -transformed titers.  
GMFR will be calculated as anti -logarithm of the mean of the log -transformed fold rise ( fi) in 
titer values, at a specific post baseline time point defined as :  
f i = v post/vpre 
where vpost is the post vaccination value of the titer at that specific post baseline time point and 
vpre is the pre vaccination baseline value of the titer , i.e., anti-logarithm of ‚àë (log transformed 
(post -vaccination titer/ pre -vaccination titer)/n),  where n is the number of subjects with non 
missing titer information at both pre and post baseline visits.  The GSD and 95% CIs for GMFR 
will be calculated similarly to those for GMT.   
In addition, statistical analyses utilizing an ANCOVA model w ill be performed for the 
continuous endpoints listed above. An ANCOVA model will be run separately at each study visit 
corresponding to Day 36, Day 57, Day 211, and Day 393 only, within each elderly age group, 
and overall. The model will be used to perform  pre-specified pairwise comparisons (a, b, c, d , e), 
including treatment arm as a fixed factor and baseline values as a covariate. Treatment arm A5 
will be included in the analysis model in order to serve as reference.  
More formally the following model:  
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
125 3DJHRI
6WDWLVWLFDO$QDO\VLV 3ODQ)LQDO )HEUXDU\

ORJYLMSRVW »ïWUHDWPHQW M»ïORJYLMSUHHLM
ZKHUHORJ YLMSRVWLVWKHORJWUDQVIRUPHGWLWHUYDOXH DWWKHVSHFLILFSRVWEDVHO LQHVWXG\GD\DQG
ORJYLMSUHLVWKHORJWUDQVIRUPHGWLWHUYDOXHDWEDVHOLQHIRUVXEMHFWL LQWUHDWPHQWDUPM $
 $ $ $DQG $
)RUEHWZHHQWUHDWPHQWDUPVDQDO\VH VIRUDOOHOGHUO\DJHJURXSV FRPELQHG¬±¬±DQG
¬ï\HDUVZKHQSHUIRUPLQJSUH VSHFLILHGSD LUZLVHFRPSDULVRQV ¬µD¬∂¬µE¬∂¬µG¬∂DQG¬µH¬∂DQ
DGGLWLRQDODJHJURXSIL[HGID FWRUZLWKOHYHOV¬±¬± DQG¬ï\HDUVZLOOEHDGGHGWR
WKHPRGHOWRXWLOL]HWKHDJHVWUDWLILFDWLRQLQIRUPDWLRQSUHVHQW ZLWKLQWUHDWPHQWDUPV $$$
DQG$,QWKLVFDVHWKH\RXQJHUDGXOWVWUHDWPHQWDUP $ZLOOQRWEHLQFOXGHGDVDOHYHOVLQFH
HOGHUO\SRSXODWLRQWUHDWPHQWDUPV $$$DQG$GRQRWVKDUHWKHVDPHDJHVWUDWLILFDWLRQDV
WKH\RXQJHUDGXOWVWUHDWPHQWDUP $:KHQSHUIRUPLQJSUHVSHF LILHGSDLUZLVHFRPSDULVRQV¬µF¬∂D
VLPLODUPRGHODVWKHRQHGHVFULEH GLQWKHSUHYLRXVSDUDJUDSKZL OOEHXVHG
8VLQJWKHPRGHOGHVFULEHGDERYHWKH*07 HVWLPDWHVIRUHDFKWUHD WPHQWDUPZLOOEHSURYLGHGE\
WUDQVIRUPLQJEDFNWRRULJLQDOVFD OHE\H[SRQHQWLDWLRQRIWKHOH DVWVTXDUHVPHDQV/60VIRUHDFK
WUHDWPHQWDUP,QDGGLWLRQWKH JHRPHWULFPHDQUDWLRDQGDVVRFL DWHG&,RIWKH
FRUUHVSRQGLQJSDLUZLVHFRPSDU LVRQZLOOEHSURYLGHGE\WUDQVIRUP LQJEDFNWRRULJLQDOVFDOHE\
H[SRQHQWLDWLRQRIWKHOHDVWVTXD UHVPHDQV/60VRIWKHWUHDWPH QWDUPGLIIHUHQFH)LQDOO\DS
YDOXHIRUWKHDVVHVVPHQWRIHDFKS DLUZLVHFRPSDULVRQZLOOEHSU RYLGHG
$VLPLODUPRGHOZLOODOVREHXVHGWRSHU IRUPSDLUZLVHFRPSDULVR QEHWZHHQWUHDWPHQWDUPVEDVHG
RQORJWUDQVIRUPHGIROGULVH ILLQWLWHUYDOXHV,QWKLVFDVHWKH* 0)5HVWLPDWHVIRUHDFK
WUHDWPHQWDUPZLOOEHSURYLGHGE\ WUDQVIRUPLQJEDFNWRRULJLQDO VFDOHE\H[SRQHQWLDWLRQRIWKH
OHDVWVTXDUHVPHDQV/60VRIHDF KWUHDWPHQWDUP,QDGGLWLRQW KHJHRPHWULFPHDQUDWLRDQG
DVVRFLDWHG&,RIWKHRIWKHF RUUHVSRQGLQJSDLUZLVHFRPSDUL VRQZLOOEHSURYLGHGE\
WUDQVIRUPLQJEDFNWRRULJLQDOVFD OHE\H[SRQHQWLDWLRQRIWKHOH DVWVTXDUHVPHDQV/60VRIWKH
WUHDWPHQWDUPGLIIHUHQFH)LQDOO \DSYDOXHIRUWKHDVVHVVPHQW RIHDFKSDLUZLVHFRPSDULVRQZLOO
EHSURYLGHG
$GGLWLRQDO,PPXQRJHQLFLW\(QGSRLQWV
CCI
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of UseDQGDQG
DQQ
HDGGHGDGGH
PVPV$$$
DVDOHYDVDOHY
HDJHVWUDJHVWU
DLUZLVHFLUZLV
XVHGVHG
DWPHQWDWPHQW
DVWVTXDUDVWVTX
VRFLDWHGRFLDWH
WUDQVIRUPWUDQVIR
WKHWUHDWPKHWUH
VRQZLOORQZLO
DLUZLVHUZLVH
HV,QWKV,QW
RUPLQJEUPLQJ
HDWPHQWDWPHQ
UUHVSRQGUHVSRQ
DOHE\H[HE\H
DOO\DSO\DS
PPXQRJPXQR
on
ty of [COMPANY_005]: For no
125 3DJHRI
6WDWLVWLFDO$QDO\VLV 3ODQ)LQDO )HEUXDU\
CCI
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Usey of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Us
NOR -204 Page 32 of 41 
Statistical Analysis Plan ( Final 1 .0) 02 February 2017  
 
7.9 Pharmacokinetic/Pharmacodynamic Analysis  
Not applicable.   
7.9.[ADDRESS_275262] instance and by [CONTACT_228684].  
In general, data imputation will not be performed for any missing safety data. The biologically 
implausible measurements for body temperature and solicited local symptoms are provided in 
Table 4 . Any measurements meeting those criteria will be excluded from the summaries and 
analyses,  but included in the data listings.  
Table 4 Definitions of implausible measurements  
Parameters  Criteria  
Body temperature (collected in diary data)  < 35¬∞C or > 42¬∞C  
Erythema  >50.0 cm  
Induration  >50.0 cm  
Swelling  >50.[ADDRESS_275263] will be assessed for reactogenicity by 
[CONTACT_1697]/staff for at least 30 minutes including observation for solicited AEs, including local 
AEs (injection site: pain, erythema, induration and swelling) and systemic AEs (headache, 
fatigue, myalgia, arthralgia, vomiting, and diarrhea), as well as body temperature measurement. 
Furthermore reactogenicity will be assessed for 7 days following each vaccination (the day of 
vaccination and the following 6 days) via diary card completion and collection of solicited AEs, 
including local AEs (injection site: pain, erythema, induration and swelling) and systemic AEs 
(headache, fatigue, myalgia, arthralgia, vomiting, diarrhea, body temperature).  
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
NOR -204 Page 33 of 41 
Statistical Analysis Plan ( Final 1 .0) 02 February 2017  
 
The categories for each s olicited AE are defined in Section 10.1.3  of the protocol [ 1, 2]. Pain is 
summarized as either none or any: where "any" will be broken down into the following 
categories: mild, moderate, and severe. Erythema, swelling and induration are recorded as yes or 
no, where the defin ition of "yes" is any area >= 25 m m; and "yes" will be further broken down 
into the following categories: >= 25 mm - <= 50 mm, > 50 mm - <= 100 mm, and > 100 m m. 
Severity categories for erythema, induration and swelling will be displayed in summary tables as: 
Mild: >=25 -<=50 mm, Moderate: >50 -<=100 mm, Seve re: >100 mm, Any: >=25 mm, None: 
<25 mm.                                                                                                   
Body temperature will be categorized as fever present (>= 100.4¬∫F, >=38oC) or fever absent (< 
100.4¬∫F, < 38oC). For t hose subjects with fever present this will be further categorized as 
provided in Table 5 . 
Unless otherwise specified, the categories based on the Celsius (with 0.5 oC increment) will be 
provided in the summary table.  Conversion from Fahrenheit to Celsius as follows:  
‚Ä¢ Body Temperature in Celsius = (Body Temperature in Fahrenheit ‚Äì 32) x (5/9)  
Table 5 Fever Categorization[3] 
Fever Present?  Body Temperatures oC (oF) 
No < 38.0oC                   (< 100.4¬∫F)  
Yes 38.0 oC ‚Äì <38.5 oC       (100.4 oF ‚Äì <101.2 oF)  
38.5 oC ‚Äì <39 oC       (101.2 oF ‚Äì <102.1 oF) 
39.0 oC ‚Äì <39.5 oC       (102.1 oF ‚Äì <103.1 oF) 
39.5 oC ‚Äì <40.0 oC       (103.1 oF ‚Äì <104.0 oF) 
>= 40.0 oC                     (>= 104.0 ¬∫F)  
For each solicited (local and systemic) AE assessment 30 minutes after each vaccination the 
percentage of subjects reporting an event will be summarized by [CONTACT_228685] (first dose or second dose) and overall (after any dose). Addition ally, the relationship 
of solicited systemic symptoms 30 minutes after each vaccination will be tabulated.  
The number and percentage of subjects without any solicited AE (Local, Systemic or Body 
Temperature) within 7 days following each vaccination (inclu ding the day of vaccination) will be 
summarized for each vaccination dose.  
Further more, for each solicited AE collected via diary cards, the percentage of subjects will be 
summarized by [CONTACT_228686] 1 to Day 7 following each vaccin ation 
(including the day of vaccination) and overall. In addition, summaries will be provided for the 
intervals of Days 1 to 3 and Days 4 to 7 following each vaccination. For subjects with more than 
1 epi[INVESTIGATOR_228662] (overall w ithin the 7 days following vaccination, 
days 1 -3, and days 4 -7), the maximum severity will be used for tabulations.  
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
NOR -204 Page 34 of 41 
Statistical Analysis Plan ( Final 1 .0) [ADDRESS_275264] 7 days following each dose, regardless of whether the 
symptom was reported on consecutive d ays (e.g. a headache reported on Day 1 and on Days 3 
and 4 would be included as 3 days). In the case when the event was ongoing at Day [ADDRESS_275265] onset of each event will a lso be provided for each vaccination.  
For all summaries by [CONTACT_228687], summaries after any vaccination will also be included.  
All tabular summaries of solicited AEs will be presented by [CONTACT_228671]. 
Additionally, summaries of solicited adverse events within 7 days after vaccination will include 
summaries by [CONTACT_228675] (overall age groups and within age group), where ‚ÄòMPL -‚Äò 
groupi[INVESTIGATOR_228663] A treatment arms ( A1 and A2) and 
‚ÄòMPL+‚Äô groupin g will summarize results over the formulation B treatment arms ( A3 and A4). 
Unsolicited AEs  
Unsolicited AEs, SAEs and AESI will be coded using MedDRA dictionary.  
Any unsolicited AEs are collected for 28 days following each vaccination (day of vaccination +  
27 days).  SAEs and AEs leading to subject withdrawal from the trial is collected throughout the 
trial from Day [ADDRESS_275266] of AESI is summarized in 
Appendix A . AESI are collected by [CONTACT_228688] 1 up to Day 393 using the 
relevant AE CRF page.  
Definition of unsolicited AEs, SAEs and AESI are provided in Sections 10.1.1 , 10.1.3 and 10.1.4 
of the protocol [ 1, 2] respectively.  
Whilst the investigator‚Äôs identification of AESI are present on the study database, for the purpose 
of reporting, AESI will be identified programmatically  via a reference a list of relevant s pecific 
PTs provided by [CONTACT_11750]. AESI identified based on this process will be reported in the relevant 
tables and listings. Therefore, the investigator assignment of AESI (identified on the relevant AE 
CRF page file) will not be utilized for reporting purp oses.  
In general unsolicited AEs will be tabulated at each of the following levels: overall summary 
(subject with at least 1 AE) and by [CONTACT_228689].   Subjects reporting more than 1 occurrence for the term (level) being 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
NOR -204 Page 35 of 41 
Statistical Analysis Plan ( Final 1 .0) [ADDRESS_275267] will be counted only once 
within each SOC and within each PT, or the overall category.  
Unless otherwise specified, unsolicited AEs will be summarized in the following 3 w ays as 
needed:  
1) overall up to 28 days after each vaccination (day of vaccination + 27 days),  
2) with onset between 1 and 7 days after each vaccination (day of vaccination + 6 days), 
and  
3) overall up to end of study   
Unsolicited AEs will be summarized  as follows:  
‚Ä¢ Overview (Unsolicited AEs, AESI, SAEs, Deaths) for 1, 2, 3;   
‚Ä¢ by [CONTACT_228690] 1, 2;   
‚Ä¢ by [CONTACT_228691] 1;  
‚Ä¢ by [CONTACT_228692] 1;  
‚Ä¢ by [CONTACT_185674] 2%, of all subjects in each 
treatment arm, up to 28 days after either vacci nation (day of vaccination + 27 days);  
‚Ä¢ by [CONTACT_3592] (Non -serious Unsolicited AEs) including events with frequency 
greater than 2%, of all subjects in each treatment arm, up to 28 days after either 
vaccination (day of vaccination + 27 days);  
‚Ä¢ by [CONTACT_2946], PT, and relationship (not related, related) to IMP for 1, 2;  
‚Ä¢ by [CONTACT_3592] (IMP-related Unsolicited AEs ) for 1;  
‚Ä¢ by [CONTACT_2946], PT, and maximum severity (mild, moderate, severe) for 1, 2;  
‚Ä¢ by [CONTACT_2946], PT, and maximum severity (mild, moderate, severe) includin g only those 
events considered related to IMP for 1;  
If a subject reported more than one AE within a SOC or PT, then the AE with the highest known 
severity or most closely related occurrence within each SOC and each PT will be included in the 
summaries by [CONTACT_228693], respectively. If an AE with a start date at or after the first 
dose has a missing severity or relationship information, then this will be imputed using a worst 
case approach, i.e. missing severity will be imputed as ‚Äòsevere‚Äô and m issing relationship will be 
imputed as ‚Äòrelated‚Äô.  
Unsolicited AEs will be assigned to vaccine dose (1st, 2nd). All summaries described in this 
section will be generated by [CONTACT_228694] (except for those summaries reporting events 
with frequency grea ter than 2%).  Summaries by [CONTACT_228695].  
In addition all AEs collected throughout the trial and identified as SAEs, AESI or AEs leading to 
study discontinuation will be summarized by [CONTACT_228696].  
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
NOR -204 Page 36 of 41 
Statistical Analysis Plan ( Final 1 .0) 02 February 2017  
 
All tabular summaries of AEs will be presented by [CONTACT_228671]. 
Additionally, the Overview table described above, will include summaries by [CONTACT_228675]  
(overall age groups and within age group), where ‚ÄòMPL -‚Äò groupi[INVESTIGATOR_228664] A treatment arms ( A1 and A2) and ‚ÄòMPL+‚Äô groupi[INVESTIGATOR_228665] B treatment arms ( A3 and A4). 
The listings for SAEs, AESI, AEs leading to study discontinuation, and AEs resul ting in death 
will be provided.  
7.11.2  Clinical Laboratory Evaluations  
Not applicable (not as a routine procedure in the protocol [ 1, 2]). 
7.11.3  Vital Signs  
The vital signs collected in the trial include: systolic blood pressure, diastolic blood pressure, 
heart rate and body temperature. Vital signs will be summarized descriptively by [CONTACT_228697], at scheduled time points. The change from baseline to 
each scheduled post -baseline time point will also be presented. Measurement parameters will be 
presented alphabetically. All data will be listed as wel l. 
7.11.[ADDRESS_275268] vaccine 
administration. A detailed physical examination includes but is not limited to: height and weig ht, 
auscultation of heart and lungs, palpation of the abdomen, inspection of extremities (including 
skin over intended vaccination site), and a check of general appearance. Additional physical 
examinations may be performed if indicated by [CONTACT_228698]‚Äôs medical history. 
Symptom -directed physical examination may be performed during the trial visits if deemed 
necessary. All data will only be listed.  
7.[ADDRESS_275269] completed the Day 36 Visit ([ADDRESS_275270] vaccination)  to verify if safety results 
observed in the present trial are consistent with what has been observed in previous trials with 
the NoV GI.1/GII.[ADDRESS_275271] approximately 100 subjects equally distributed in each permutation. DMC Tables, and 
Listings to be p resented during the DMC sessions are identified in Appendix B . 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
NOR -204 Page 37 of 41 
Statistical Analysis Plan ( Final 1 .0) [ADDRESS_275272] 
completed the Day  57 Visit ([ADDRESS_275273] vaccination). This analysis will include group 
results but not individual subject information.  
Each of the DMC safety review and interim analysis will be performed by a team of unblinded 
statisticians and programmers at [COMPANY_003] who will have access to individual treatment assignments 
but will not be involved in subsequent trial conduct. With exception of the unblinded pharmacist 
and unblinded administrator, the personnel involved in the conduct of the trial including those at 
the Spo nsor site, at [COMPANY_003], and the trial sites, will remain blinded to the individual subject data 
(including treatment assignment) until unblinding after database lock for data through Day 393.  
The list of team members from the study who will gain access to unbli nded treatment codes and 
outputs will be documented in an unblinding plan.  
7.13 Changes in the Statistical Analysis Plan  
Not applicable  
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
NOR -204 Page 38 of 41 
Statistical Analysis Plan ( Final 1 .0) 02 February 2017  
 
8.0 REFERENCES  
1. A Phase II, Randomized, Controlled, Double -Blind, Safety and Immunogenicity Trial of 
Norovirus GI.1/GII.4 Bivalen t Virus -Like Particle Vaccine in Healthy Elderly Adults,  
[COMPANY_005] Vaccines, Inc., Protocol No. NOR -204, dated 16 July, 2015.  
2. A Phase II, Randomized, Controlled, Double -Blind, Safety and Immunogenicity Trial of 
Norovirus GI.1/GII.4 Bivalent Virus -Like Partic le Vaccine in Healthy Elderly Adults,  
[COMPANY_005] Vaccines, Inc., Protocol No. NOR -204, dated 16 November, 2015.  
3. Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers 
Enrolled in Preventive Vaccine Clinical Trials  
4. Li, X, Wan g, W. Liu, G. and Chan, I, Handling Missing Data in Vaccine Clinical Trials for 
Immunogenicity and Safety Evaluation. Journal of Biopharmaceutical Statistics, 2011, 21(2), 
294-310 
  
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
NOR -204 Page 39 of 41 
Statistical Analysis Plan ( Final 1 .0) [ADDRESS_275274] (AESI)  
Cardiac Disorders  
‚Ä¢ Endocarditis  ‚Ä¢ Pericarditis  
‚Ä¢ Myocarditis   
Gastrointestinal Disorders  
‚Ä¢ Celiac Disease  ‚Ä¢ Ulcerative Colitis  
‚Ä¢ Crohn's Disease  ‚Ä¢ Ulcerative Proctitis  
‚Ä¢ Inflammatory Bowel Disease (non -specific)   
Immune System Disorders  
‚Ä¢ ANA Increased  ‚Ä¢ Autoimmune Hemolytic Anemia  
‚Ä¢ Anti-ds DNA Increased  ‚Ä¢ Autoimmune Hepatitis  
‚Ä¢ Anti-Phospholipid Syndrome  ‚Ä¢ Idiopathic thrombocytopenic purpura (ITP)  
‚Ä¢ Autoimmune Glomerulonephritis  ‚Ä¢ Serum Sickness  
Infections and Infestations  
‚Ä¢ Fever of Unknown Origin  ‚Ä¢ Sinusitis  
Musculoskeletal and Connective Tissue Diseases  
‚Ä¢ ANCA -Associated Vasculitis  ‚Ä¢ Polymyositis  
‚Ä¢ Arthritis/Bursitis (non -specified)  ‚Ä¢ Reactive Arthritis  
‚Ä¢ Behcet‚Äôs Syndrome  ‚Ä¢ Rheumatoid Arthritis  
‚Ä¢ Cutaneous Lupus  ‚Ä¢ Sarcoidosis  
‚Ä¢ Dermatomyositis  ‚Ä¢ Scleroderma  
‚Ä¢ Juvenile Rheumatoid Arthritis  ‚Ä¢ Sjorgen‚Äôs Syndrome  
‚Ä¢ Mixed Connective Tissue Disease  ‚Ä¢ Systemic Lupus Erythematosis  
‚Ä¢ Mono -Articular Arthritis  ‚Ä¢ Temporal Arteritis  
‚Ä¢ Pauci -Articular Arthritis  ‚Ä¢ Wegener‚Äôs Granulomatosis  
‚Ä¢ Polymyalgia Rheumatica   
Neuroinflammatory Disorders  
‚Ä¢ Acute disseminated encephalomyelitis (ADEM)  ‚Ä¢ Myasthenia Gravis  
‚Ä¢ Bell's Palsy/Facial Palsy  ‚Ä¢ Myelitis/Transverse Myelitis  
‚Ä¢ Encephalitis  ‚Ä¢ Neuritis  
‚Ä¢ Demyelinating Disease  ‚Ä¢ Optic Neuritis  
‚Ä¢ Guillain Barr√© Syndrome  ‚Ä¢ Paraesthesia (non -specific)  
‚Ä¢ Hypoaesthesia (non -specific)  ‚Ä¢ Uveitis  
‚Ä¢ Multiple Sclerosis   
Renal and Urinary Disorders  
‚Ä¢ Glomerulonephritis  ‚Ä¢ Proteinuria  
‚Ä¢ Hematuria  ‚Ä¢ Renal failure  
‚Ä¢ Nephritis   
Skin  
‚Ä¢ Alopecia  ‚Ä¢ Stevens -Johnson Syndrome  
‚Ä¢ Dermatomyositis  ‚Ä¢ Toxic Epi[INVESTIGATOR_19342] (TEN)  
‚Ä¢ Erythema Nodosum  ‚Ä¢ Vitiligo  
‚Ä¢ Psoriasis and Psoriatic Arthropathy   
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
NOR -204 Page 40 of 41 
Statistical Analysis Plan ( Final 1 .0) 02 February 2017  
 
Thyroid Disorders  
‚Ä¢ Graves' (Basedow's) Disease  ‚Ä¢ TSH High  
‚Ä¢ Goiter (non -specified)  ‚Ä¢ Thyroid Disorder (non -specific)  
‚Ä¢ Hyperthyroidism  ‚Ä¢ Thyroiditis  
‚Ä¢ Hypothyroidism   
Vascular Disorders  
‚Ä¢ Pulmonary Embolism  ‚Ä¢ Vasculitis  
‚Ä¢ Raynaud's Phenomenon   
Others   
‚Ä¢ Aphthous Stomatitis  ‚Ä¢ Insulin -dependent diabetes mellitus (IDDM)  
  
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
NOR -204 Page 41 of 41 
Statistical Analysis Plan ( Final 1 .0) 02 February 2017  
 
Appendix B  Data Monitoring Committee (DMC) Outputs  
The following Tables and Listings will be provided during the DMC sessions. Treatment 
information for blinded and unblinded reports will be handled accordingly.  
DMC ID  Full TLF Shell ID  Title  Analysis Set  
Tables     
DMC Table 1  Table 15.1.5  Disposition of Subjects  All Randomized Subjects  
DMC Table 2  Table [IP_ADDRESS]  Demographics and Baseline Characteristics  All Randomized Subjects  
DMC Table 3  Table [IP_ADDRESS].1  Summary of Subjects without Solicited Adverse 
Events (Local, Systemic or Body Temperature) 
within 7 Days After each Vaccination  Safety Analysis Set  
DMC Table 4  Table [IP_ADDRESS].1  Summary of Solicited Local Adverse Events within 7 
Days After each Vaccination  Safety Ana lysis Set  
DMC Table 5  Table [IP_ADDRESS].2  Summary of Solicited Systemic Adverse Events 
within 7 Days After each Vaccination  Safety Analysis Set  
DMC Table 6  Table [IP_ADDRESS].1  Summary (Daily) of Solicited Local Adverse Events 
Within 7 Days After each Vaccinati on Safety Analysis Set  
DMC Table 7  Table [IP_ADDRESS].2  Summary (Daily) of Solicited Systemic Adverse 
Events within 7 Days After each 
Vaccination  Safety Analysis Set  
DMC Table 8  Table [IP_ADDRESS].1  Unsolicited Adverse Events Up to 28 
Days After Vaccination by [CONTACT_228699] 9  Table [IP_ADDRESS]  Serious Adverse Events after each 
Vaccination by [CONTACT_228700] 10  Table [IP_ADDRESS]  Adverse Events of Special Interest  
After each Vaccination by [CONTACT_228701] 1  Appendix [IP_ADDRESS]  
 Disposition ‚Äì Vaccine Regimen  All Randomized Subjects  
DMC Appendix 2  Appendix [IP_ADDRESS]  Disposition ‚Äì Study Visits  All Randomized Subjects  
DMC Appendix 3  Appendix [IP_ADDRESS]  Demographics and Baseline Characteristics  All Randomized Subjects  
DMC Appendix 4  Appendix [IP_ADDRESS]  Study Treatment Administration  Safety Analysis Set  
DMC Appendix 5  Appendix [IP_ADDRESS]  Solicited Local A dverse Events  Safety Analysis Set  
DMC Appendix 6  Appendix [IP_ADDRESS]  Solicited Systemic Adverse Events  Safety Analysis Set  
DMC Appendix 7  Appendix [IP_ADDRESS]  Diary Body Temperature  Safety Analysis Set  
DMC Appendix 8  Appendix [IP_ADDRESS]  Adverse Events  Safety Analysis Set  
DMC Appendix 9  Appendix [IP_ADDRESS]  Serious Adverse Events  Safety Analysis Set  
DMC Appendix 10  Appendix [IP_ADDRESS]  Adverse Events of Special Interest  Safety Analysis Set  
 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use